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The opioid system, comprised mainly of the three opioid receptors (kappa, mu and delta) 
and their endogenous neuropeptide ligands (dynorphin, endorphin and enkephalin, respectively), 
mediates mood and reward. Activation of the mu opioid receptor is associated with positive 
reward and euphoria, while activation of the kappa opioid receptor (KOR) has the opposite 
effect. Activation of the KOR causes a decrease in dopamine levels in reward-related regions of 
the brain, and can block the rewarding effects of various drugs of abuse, making it a potential 
drug target for addictive diseases. KOR agonists are of particular interest for the treatment of 
cocaine and other psychostimulant addictions, because there are currently no available 
medications for these diseases. Studies in humans and animals, however, have shown that 
activation of the KOR also causes negative side effects such as hallucinations, aversion and 
sedation.  
Several strategies are currently being employed to develop KOR agonists that block the 
rewarding effects of drugs of abuse with fewer side effects, including KOR agonists with unique 
pharmacology. The goal of the research presented here was to profile the signaling pathways 
activated by KOR agonists and to investigate relationships between unique pharmacology and 
animal models of KOR-mediated behaviors, in order to better understand how to target the KOR 
for therapeutic use.  
 First, we quantified the effects of KOR agonists at both G-protein and b-arrestin-2 
signaling pathways to compare to a variety of downstream effects, including sedation behavior. 
We found that b-arrestin-2, but not G-protein, efficacy strongly correlated with sedation in mice. 
We found that there was no apparent relationship between either G-protein or b-arrestin-2 
signaling pathways with other investigated downstream signaling pathways, such as ERK1/2 and 
mTOR, however. We also investigated the effects of KOR activation on protein-receptor 
interactions, to identify other potential mediators of KOR effects.  
 Finally, we compared the effects of several unique KOR agonists on addiction-related 
behaviors in mice. We found that nalfurafine, which is approved for human use in Japan, very 
potent KOR agonist, was able to modulate the rewarding effects of cocaine at very low doses 
that did not cause sedation or aversion. We also found that the commonly-used, full KOR agonist 
U50,488 had a similar effect, suggesting that this “therapeutic window” could be a property of 
the KOR system in general. Overall, this work suggests that KOR agonists at very low doses, 
that show very little b-arrestin-2 signaling activity, may be able to modulate the rewarding 
effects of cocaine while causing fewer negative side effects.
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CHAPTER 1. BACKGROUND AND GOALS 
1.1 Opioid receptors mediate mood and reward, including addiction 
With the rise of the “opiate epidemic” in recent years, addictions have come to the forefront 
of the national conversation on health. Research has led to better understanding of some factors 
that contribute to specific addictive diseases, leading to improved treatment options for some. 
Addiction to opiate drugs like heroin, that target the mu opioid receptor, can be treated 
effectively with medication-assisted therapy with drugs such as methadone and buprenorphine.6 
Fewer effective options are available for those addicted to alcohol, however, and there are 
currently no medication-assisted therapies for addiction to cocaine, methamphetamine and other 
psychostimulants, which affect over 1 million people in the United States alone.1 Understanding 
more about the different systems in the brain and body that are involved in addictive diseases, 
such as the opioid system, can lead to better understanding of the disease, and better treatment 
options. 
Humans have used drugs that target opioid receptors for centuries for medicinal, and later 
recreational, purposes, although the targets themselves weren’t discovered until the 1970’s. 
Scientists used the displacement of radiolabeled naloxone in homogenized rodent brain tissue to 
prove the existence of opioid receptors as specific and saturable binding sites for opioid drugs in 
1973.2–4 It had long been hypothesized that there were several different opioid receptor subtypes, 
based on the varying pharmacological properties of the different opioid drugs available to test in 
human and animal models.5 Before they were definitively proven, two of these receptors were 
named for the actions of different opioid drugs – the mu opioid receptor for its binding of 
morphine and the kappa opioid receptor for its binding of the benzomorphan drug 
ketocyclazocine.6 These opioid drugs with distinct pharmacological properties were eventually 
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used to identify receptor subtypes. For example, a tritiated benzomorphan compound was used to 
identify binding sites that were consistent with the pharmacological properties of this putative 
kappa opioid receptor in guinea pig cerebellum.7 The delta opioid receptor was named later, 
when it was found to be enriched in mouse vas deferens tissue.8 By the early 1990’s, scientists 
had identified and cloned the three main opioid receptor subtypes.9–13  
The three main opioid receptors (KOR, MOR and DOR) and their endogenous peptide 
ligands (dynorphins, endorphins and enkephalins) are now recognized as crucial mediators of 
mood and reward, as well as pain and other sensations. Genetic and pharmacological studies 
have shown that the MOR system is necessary for the rewarding and euphoria-inducing 
properties of many drugs of abuse, including MOR agonists like morphine and drugs of abuse 
with different mechanisms of action, such as alcohol (reviewed in Darcq and Kieffer, 2018).14 
The DOR system is thought to mediate mood, as DOR agonists are anxiolytic and cause anti-
depressant like behavior in animal models and DOR knock-out mice have increased anxiety and 
depressive-like behavior.15 The KOR system, on the other hand, appears to negatively regulate 
both mood and reward (Figure 1.1). 
 
 
Figure 1.1. Opioid receptor systems differentially mediate mood and reward 
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1.2 The KOR system negatively regulates reward 
In addition to causing the antinociceptive effects characteristic of most opioid agonists, KOR 
agonists have been shown repeatedly to be aversive and dysphoric in both animal and human 
studies. Early studies in rats found that the activation of KORs and MORs by small molecules 
had opposing effects on dopamine release in reward-related regions of the brain; while MOR 
agonists stimulated dopamine release, KOR agonists decreased dopamine release.16 Activation of 
KORs by the endogenous peptide ligand dynorphin A (1-17) also led to a decrease in dopamine 
release. 17 This is thought to be the mechanism through which the KOR system mediates 
negative affect naturally. In animal models, for example, stressful experiences lead to negative 
affect, as demonstrated by depressive and anxiety-like behaviors, and this process is mediated by 
the KOR system.18,19 Both KOR and dynorphin expression appear to be upregulated following 
administration of drugs such as morphine and cocaine in animal models,20–22 as well as after 
cocaine overdose in humans,23 suggesting that the KOR system may also be involved in the 
development of negative affective states in the addiction process. 
Because of its anti-reward properties and role in addiction, many groups have investigated 
the KOR as a potential therapeutic target for the treatment of addictive diseases. KOR agonists 
have been shown to block the rewarding and reinforcing effects of several different drugs of 
abuse in animal models such as self-administration and conditioned-place preference (reviewed 
in Banks 2019).24 These drugs include cocaine, ethanol, and MOR agonists such as morphine. 
Further, work from Yong Zhang has shown that activation of the KOR by dynorphin A (1-17) 
can block the dopaminergic surge caused by cocaine in mice, suggesting a mechanism for this 
reward blockade.17  
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In models of stress-induced reinstatement of drug seeking, however, the KOR system appears 
to potentiate reinstatement.19,25 Additionally, there have been studies demonstrating that KOR 
agonists potentiate drug reward under certain circumstances in animal models.24 It is clear that 
the KOR plays an important and complex role in the regulation of drug reward, and research is 
ongoing to determine the best way to therapeutically target this receptor for the treatment of 
addictive diseases. KOR agonists are particularly interesting for the treatment of cocaine and 
other psychostimulant addictions, as there are currently no available medications for these 
diseases.   
1.3 Many KOR agonists have negative side effects in humans  
Human studies have revealed negative side effects of KOR agonists that have hampered 
drug development. In the 90’s and early 2000’s, the KOR-selective arylacetamide agonists 
spiradoline (U69,066E) and enadoline were tested for analgesic efficacy in humans. Two studies 
of enadoline in 1996 for post-operative and dental pain showed no effect of the KOR agonist on 
analgesia overall.26,27 While the highest dose of enadoline tested did decrease some reports of 
post-operative pain, the study had to be terminated early because of “neuropsychiatric events”, 
including psychotomimetic effects and hallucinations.27 Studies of spiradoline similarly found 
that this compound caused significant sedation in humans, as well as dysphoria, and that it could 
not replace MOR analgesics because of these side effects (reviewed in Wadenburg 2003).28  
 Shortly after these clinical studies, scientists also identified the KOR as the target for the 
main psychoactive compound in the plant Salvia divinorum.29,30 Leaves from this plant have 
been used for centuries by the Mazatec people of Oaxaca, Mexico as part of their spiritual rituals 
and practices, and more recently as a recreational hallucinogen in parts of Mexico and the United 
States. The active compound, salvinorin A, was isolated in the 1980’s and its molecular target 
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was identified as the kappa opioid receptor by Bryan Roth in the early 2000’s. 29 The potent 
hallucinogenic properties of salvinorin A, as well as reports of sedation and dysphoria in Salvia 
divinorum users, helped to confirm the effects of KOR agonist activity in humans, in addition to 
providing a new scaffold for the development of unique kappa opioid compounds.31  
 Despite the adverse effects displayed by KOR agonists, there are some compounds 
currently in clinical use that target the KOR. Nalmefene is currently approved to treat alcohol 
addiction in Europe, and naltrexone is approved in the US for the treatment of opioid and alcohol 
addiction. Nalmefene and naltrexone are both MOR antagonists that have recently been shown to 
have partial KOR agonism for signaling through G-proteins.32–34 Neither drug appears to cause 
the psychotomimetic, sedative or dysphoric side effects that are common to KOR agonists, 
however, suggesting that their partial agonism or signaling profile at the KOR may be beneficial 
for therapeutic development.  
 The only KOR-selective agonist that is used in humans is the compound nalfurafine, 
approved in Japan to treat pruritus in 2009. It is extremely potent, with a daily oral dose of 2.5µg 
for adults. While the reported KOR-mediated signaling properties of nalfurafine vary among 
studies, likely due to differences in assays and cell lines, it has been shown to have full efficacy 
at the KOR for almost all signaling pathways.35,36  Post-marketing studies have demonstrated 
very few of the side effects expected with KOR agonism.37 Additional studies in animals have 
examined the “therapeutic window” for nalfurafine dosing, between the doses that cause the 
desired antinociceptive and antipruritic therapeutic effects and the doses that cause negative side 
effects like sedation, and generally found that nalfurafine does not cause negative side effects at 
therapeutic doses. Other KOR agonists such as salvinorin A and the well-characterized 
arylacetamide agonist U50,488 tested in the same studies, however, caused negative side effects 
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at the same doses needed for therapeutic effects in these antinociceptive and antipruritic 
assays.35,38,39 Initial studies have demonstrated that nalfurafine modulates the rewarding effects 
of drugs of abuse as well, although it is unclear how this effect compares with other KOR 
agonists.  
 Finally, KOR antagonists have been tested preclinically for different therapeutic 
indications including anti-depressant and anti-addictive properties.40 Limited human studies so 
far have not demonstrated KOR blockade to be an effective treatment for depression or 
addictions. 41,42 However the short-acting KOR antagonists that are currently under investigation 
have also not shown any negative side effects.41,42 
Together, the preclinical and clinical data suggest that KOR agonists with modified 
pharmacological properties, such as partial agonists, or agonists like nalfurafine with unique 
properties, could be potential therapeutics for treating addictive diseases, and particularly 
cocaine and other stimulant addiction.43  
 
1.4 KOR agonists activate multiple signaling pathways 
Additionally, there is a large effort to make and test agonists that selectively activate only 
certain pathways downstream of the KOR in order to confer therapeutic properties without 
causing negative side effects. The KOR, along with the other opioid receptors, is an inhibitory G-
protein coupled receptor (GPCR). Upon receptor activation, heterotrimeric G-protein activation 
leads to inhibition of cyclic AMP production and hyperpolarization via ion channel interactions. 
Phosphorylation of the receptor also leads to the recruitment of b-arrestin-2, which leads to 
receptor internalization. This receptor-arrestin complex also confers its own set of signaling 
responses that may be independent of G-protein signaling (Figure 1.2). There have been recent 
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discoveries of downstream signaling pathways of KORs that are both G-protein-dependent and 
G-protein-independent (b-arrestin-dependent), including certain mitogen-activated protein 
kinases (MAPKs) and, more recently, the mTOR signaling pathway (mammalian target of 
rapamycin) (Figure 1.2).  
 
 
Figure 1.2. G-protein coupled receptors signal through diverse pathways 
 
 Studies of genetic knockout animals have suggested that certain downstream effects in 
vivo may require specific activation of these G-protein or b-arrestin signaling pathways. 
Specifically, in arrestin-knockout mice, activation of the mu opioid receptor still caused 
analgesia, but did not cause respiratory depression, suggesting that this side effect of MOR 
agonists required b-arrestin signaling.44 This offers exciting possibilities for therapeutic 
development, as agonists that activate only one pathway could be used to elicit only a specific 
subset of downstream consequences, while excluding possible adverse effects (Figure 1.3). 
These “biased” or “functionally-selective” MOR agonists are currently being developed for pain 
relief based in part on studies from the Bohn laboratory and others reporting that G-protein 
biased MOR agonists were anti-nociceptive, but did not induce respiratory depression, in rodent 
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models.45–47 This hypothesis is still being tested in humans with the G-protein biased MOR 
agonist TRV 130 (Oliceridine).48,49   
 
 
Figure 1.3. Biased agonists may be able to selectively induce downstream effects 
 
 Efforts have also been made to characterize KOR agonist pharmacology and determine 
which behaviors involve, or even require, G-protein or b-arrestin signaling (reviewed in Mores 
2019).50 RB-64, among the first biased KOR agonists, is an analog of salvinorin A that 
preferentially activates G-protein signaling over b-arrestin-2 signaling. In animal studies, this 
compound was antinociceptive, however it did not cause the sedative effects caused by the 
unbiased KOR agonists U50,488 and salvinorin A.51 Later studies of a novel series of G-protein 
biased triazole compounds also suggested that b-arrestin signaling was necessary for the sedative 
properties of KOR agonists, but not antipruritic or antinociceptive effects.52  
There are also efforts to characterize additional novel KOR agonists, as well as 
previously-described opioid compounds, for their G-protein versus arrestin bias at the kappa 
opioid receptor. 53–55 Many of these compounds have been previously characterized in animal 
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models, and some even in humans, and understanding more about their pharmacology could help 
improve understanding of the relationships between signaling pathways and behaviors 
downstream of the KOR. These efforts, however, have highlighted some of the technical 
difficulties in assigning an agonist the label of “biased”.  
 To measure ligand bias, the activities of a compound in two different signaling pathways 
are compared. This requires selecting assays and endpoints for measuring activity, as well as a 
reference agonist to designate “full” activity in each pathway, which can vary between studies. 
Bias is most commonly quantified using the operational model of partial agonism first described 
by Black and Leff in the 1980’s.56,57 By definition, all quantifications of ligand bias are specific 
to the assays and reference agonists chosen.  
 In addition to these experimental details that can vary between labs, it has been shown 
that agonist activity downstream of a receptor can vary depending on what cellular components 
are available, meaning that measurements of ligand bias can vary between cell lines and tissues. 
This makes it difficult to compare measurements of bias between studies, and also suggests that 
in vitro measurements of ligand bias may not be indicative of signaling in disease-relevant tissue. 
Despite these concerns, a recent 2017 study from the Bohn laboratory demonstrated that an in 
vitro measurement of “Bias Factor” did in fact correlate significantly with the “therapeutic 
window”, between antinociceptive and respiratory depression effects, in mice.46 While there are 
many difficulties to measuring ligand bias, or understanding what signaling pathways are 
activated in the disease-relevant tissue, this study demonstrated that these in vitro measurements 
can be useful tools for guiding drug development efforts.   
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1.5 Additional signaling pathways may be involved in opioid receptor signaling 
 In addition to investigating G-protein and b-arrestin signaling pathways, studies have 
identified other signaling proteins that may be involved in opioid receptor effects. Several 
proteins of the MAPK family, for example, have been implicated in KOR-mediated behavior. 
The b-arrestin-dependent activation of the MAPK p38 has been shown to be important for 
mediating the aversive effects of KOR agonists.58,59 Additionally, blockade of the KOR with 
long acting antagonists has been shown to activate JNK (c-Jun N-terminal kinase) as well, 
another MAPK protein.60 ERK1/2 (extracellular related kinases 1 and 2) proteins have been 
shown to be phosphorylated after KOR activation by many different KOR agonists, and a study 
with salvinorin A suggested that ERK1/2 activation is necessary for the blockade of dopamine 
release by KOR agonists.61 An important study from the Bohn laboratory also demonstrated that 
ERK1/2 phosphorylation downstream of the KOR could be independent of G-protein or b-
arrestin activation, highlighting the importance of examining these additional signaling 
pathways.62 
 A recent phosphoproteomic study compared signaling protein activation (via 
phosphorylation patterns) in particular brain regions of mice treated with different KOR 
agonists.39 This study identified that certain KOR agonists, at doses that caused aversion, led to 
increased mTOR signaling compared to non-aversive KOR agonists. Follow-up studies indicated 
that mTOR activation was necessary for KOR-mediated aversion, but not sedation, suggesting 
that this signaling pathway may also be important to consider for the development of KOR 
agonists with fewer side effects.36 
 New techniques in biochemistry and structural biology are also being developed to 
investigate the molecular basis of opioid receptor signaling, particularly the differential 
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activation of opioid receptors by biased ligands. For example, using nanobodies that selectively 
bind the active conformation of the MOR, the Von Zastrow laboratory has identified differences 
in the subcellular localization of active MORs after treatment of cells with the endogenous b-
endorphin peptide versus small molecule agonists.63 Strategies like these could help to identify 
key relationships between drug action at the molecular level and the behavioral level, that could 
in turn aid drive drug discovery efforts.  
 
1.6 Research goals  
Data from preclinical and clinical studies of KOR ligands suggest that modified 
pharmacology, such as partial agonists or unique signaling pathway activation, could help lead to 
KOR agonists with fewer side effects. Recent advances in GPCR research also suggest that 
biased agonists, that selectively activate only certain pathways downstream of the receptor, could 
also improve side effect profiles of different compounds. Here, we have explored several 
different strategies to investigate the relationships between KOR signaling and behavior, 
including exploring biased agonists, identifying other downstream signaling pathways and 
testing compounds that have already proven to be safe in humans in preclinical mouse models of 
cocaine reward. 
 In Chapter 3, 21 structurally-diverse KOR agonists were pharmacologically profiled for 
both G-protein and b-arrestin-2 signaling, and their ligand bias in this context was quantified. 
We then examined the relationships between these early G-protein and arrestin signaling 
pathways and KOR-mediated sedation in mice, as measured by the rotarod assay. 
In Chapter 4, we examined the ability of KOR agonists to activate additional signaling 
pathways that have been more recently implicated in KOR-mediated behaviors, including 
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ERK1/2 phosphorylation and mTOR activation. We also investigated novel pathways that may 
be involved in KOR-signaling for future study.  
Finally, in Chapter 5, we examined preclinical mouse models of KOR-mediated 
behaviors using several different types of KOR agonists, including a G-protein biased agonist 
and the clinically-utilized agonist nalfurafine. We compared the effective doses of different KOR 
agonists for negative side effects, as well as models of cocaine reward and reinforcement. 
Together, the goal of this work is to better understand the different pharmacological strategies 
that could be used to develop KOR ligands for therapeutic use in the future.  
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CHAPTER 2. MATERIALS AND METHODS 
2.1. Chemical compounds 
Dynorphin A(1-17) (YGGFLRIRPKLKWDNQ) was obtained from BACHEM. GR89686 (4-
[(3,4-Dichlorophenyl)acetyl]-3-(1-pyrrolidinylmethyl)-1-piperazinecarboxylic acid methyl ester 
fumarate) was obtained from Tocris. Nor-Binaltorphimine was obtained from Abcam 
(Cambridge, UK). Salvinorin A and Mesyl Salvinorin B were given by Dr. Tom Prisinzano 
(University of Kansas). Nalmefene was obtained from Baker Norton Pharmaceuticals (Miami, 
FL, USA). Nalfurafine was obtained from Adooq Bioscience (Irvine, CA, USA). N-substituted-
[N-[2-phenylethyl]-N-[2-(3-hydroxyphenyl)ethyl]-amines (where substitutions = N-butyl for 
BPHA, cyclopropyl for HS666, methylcyclobutyl for MCBPHA and methylcyclopentyl for 
MCPPHA) were synthesized by a contract research organization, WuXi Apptech (Shanghai, 
China), using methods reported previously by the group of Schmidhammer.64 WMS 0610 (1-{4-
Benzyl-8 – pyrrolidine-1-yl-perhydroquinoxalinyl}-2-(3,4- dichlorophenyl)ethen one) and WMS 
0611(2-(3,4-Dichlorophenyl)-1-(-8- pyrrolidine-1-yl-perhydroquinoxalinyl)- ethanone ) were 
also synthesized by WuXi Apptech, using methods previously reported by the group of 
Wunsch.65 For these synthesized compounds, mass spectrometric and NMR signals were in 
agreement with previous publications. LY2444296 [(S)-3-fluoro-4-(4-((2-(3-fluorophenyl) 
pyrrolidin-1-yl) methyl)phenoxy)benzamide] was also synthesized by WuXi, with a small 
portion generously donated by Eli Lilly (Indianapolis, IN), which was used to confirm that the 
WuXi synthesized compound was molecularly identical (as determined by reversed-phase high-
performance liquid chromatography retention time). Remaining compounds were obtained from 
Sigma (St. Louis, MO, USA). This includes U69,593[(-)-(5α,7α,8β)-N-Methyl-N-[7-(1-
pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide], U50,488 [trans-(±)-3,4-Dichloro-N-
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methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide], U62,066E [(±)-(5α,7α,8β)-3,4-
Dichloro-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]benzeneacetamide], and 
ICI204448[(RS)-[3-[1-[[(3,4-Dichloro phenyl)acetyl]methylamino]-2-(1-
pyrrolidinyl)ethyl]phenoxy] acetic acid]. [3 H]U69,593, and [35 S]GTPγS were procured from 
Perkin Elmer (Waltham, MA, USA). 3G1 and 3G2 were novel compounds synthesized by WuXi 
Apptech, using methods adapted from those previously reported.64   
2.2 In vitro signaling studies 
2.2.1 b-arrestin-2 enzyme fragment complementation (ECF) 
Experiments were conducted using the PathHunter Detection Kit obtained from DiscoveRx. 
Cells stably expressing human kappa opioid receptors (PathHunter U2OS hOPRK1 β-arrestin-2 
cell line, DiscoveRx, Fremont, CA, USA) were plated in 96- or 384-well plates. Cells were 
stimulated with the compounds for 90 minutes at 37°C followed by incubation for 60 minutes in 
the presence of galactosidase substrate, yielding chemiluminescent product. All concentrations 
were tested in quadruplicate for each experiment, and had an N of 3 experiments total. Each 384-
well plate also had 32 additional replicates of 10µM U69,593 that were used for normalization. 
Chemiluminescence was measured using a Synergy Neo microplate reader (BioTek, Winooski, 
VT, USA). Antagonism assays were done in the same manner, in the presence of 300nM 
U69,593.  
2.2.2 [35S]GTPgS Binding with U2OS cell membranes 
Membranes from U2OS cells (PathHunter U2OS hOPRK1) stably expressing human KORs were 
used. Cells were scraped from tissue culture plates, homogenized with a Tissue Tearor 
homogenizer in membrane buffer (10mM Tris-HCl, 100mM NaCl, and 1mM EDTA; pH 7.4), 
and centrifuged at 20,000 g for 30 minutes at 4°C and frozen at -80°C until use. Prior to use, the 
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pellets were resuspended in assay buffer (50mM Tris-HCl, 100mM NaCl, 5mM MgCl2, and 
1mM EDTA; pH 7.4) and homogenized with a dounce homogenizer and 50 µg incubated with 
0.1nM [35 S]GTPγS, 10nM GDP, and the appropriate concentration of agonist for 20 minutes at 
30°C. All concentrations were tested in quadruplicate for each experiment, and had an N of 3 
experiments total. Membranes with bound [35 S]GTPγS were collected on Whatman GF/B filter 
paper (Brandel, Gaithersburg, MD, USA) utilizing a Brandel harvester.  Bound [35 S]GTPγS was 
quantified using  a TriCarb-2900TR scintillation counter (Packard, Downers Grove, IL, USA) 
following addition of 4 mL ReadySafe scintillation fluid (Beckman Coulter, Indianapolis, IN, 
USA).  
2.2.3 [35S]GTPgS Binding with mouse striatum tissue  
Mice were euthanized by cervical dislocation, in a manner approved by The Rockefeller 
University Institutional Animal Care and Use Committee. Ventral striatum tissue, corresponding 
to the caudate putamen and nucleus accumbens regions, was removed immediately after sacrifice 
and tissue was frozen in liquid nitrogen. Tissue samples were then stored at -80°C until further 
use. Homogenization and assay protocol were adapted from Bohn, Zhou and Ho 201566 and 
described below. 
 Striatum samples were homogenized in homogenization buffer (10mM Tris-HCl, pH 7.4, 
100mM NaCl, 1mM EDTA, 1mM DTT added immediately prior to use) by a Tissue Tearor 
homogenizor on ice, dounced in a dounce homogenizor and passed through a 26 gauge needle 
for homogenization. The tissue was then centrifuged at 20,000 g for 30 minutes at 4°C, rinsed 
with homogenization buffer and spun down again. Pellets were resuspended in assay buffer 
(50mM Tris-HCl, pH 7.4, 100mM NaCl, 5mM MgCl2, 1mM EDTA, 1mM DTT added 
immediately prior to use) and incubated with 0.1nM [35 S]GTPγS, 20 nM GDP, and the 
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appropriate concentration of agonist for 1 hour at RT. All concentrations were tested in 
quadruplicate. Membranes with bound [35 S]GTPγS were collected on Whatman GF/B filter 
paper (Brandel, Gaithersburg, MD, USA) utilizing a Brandel harvester.  Bound [35 S]GTPγS was 
quantified using  a TriCarb-2900TR scintillation counter (Packard, Downers Grove, IL, USA) 
following addition of 4 mL ReadySafe scintillation fluid (Beckman Coulter, Indianapolis, IN, 
USA). 
2.2.4 In-cell western blots for ERK1/2 phosphorylation 
HEK293 cells stably expressing a FLAG (DYKDDDDK) -tagged mouse KOR were plated in a 
96-well plate and stimulated with compound for 5 minutes after 1 hour of serum starvation. All 
concentrations were tested in triplicate. Cells were then prepared for immunofluorescent staining 
with phosphorylated ERK1/2 (Phospho-p44/p42 MAPK, 1:100, Cell Signaling Technology, 
Danvers, MA, USA) and GAPDH (GAPDH (0411), 1:100, Santa Cruz Biotechnology, Dallas, TX, 
USA) primary antibodies, and near-infrared secondary antibodies (IRDye 680CW and IRDye 
800CW, 1:500, LiCor Biosciences, Lincoln, NE, USA). Plates were imaged on the Li-Cor Odyssey 
CLx Imaging System (LiCor Biosciences, Lincoln, NE, USA).  
2.2.5 Western blots for Rps6 phosphorylation 
U2OS cells (PathHunter U2OS hOPRK1) stably expressing human KORs were plated in a 
96wwell plate and stimulated with compound for 1 hour after 14-16 hours of serum starvation. All 
concentrations were run in triplicate. Cells were lysed with radioimmunoprecipitation (RIPA) 
buffer (Thermo Fisher Scientific, Waltham, MA, USA). Samples were run on SDS PAGE gels, 
and multiple gels trimmed and transferred to a single western blot (“multistrip” western blot).67 
Blots were probed with phosphorylated Rps6 (P-S6 Ribosomal Protein (Ser240/244), 1:1000, Cell 
Signaling Technology, Danvers, MA, USA) and GAPDH (GAPDH (0411), 1:1000, Santa Cruz 
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Biotechnology, Dallas, TX, USA)  primary antibodies, and near-infrared secondary antibodies 
(IRDye 680CW and IRDye 800CW, 1:500, LiCor Biosciences, Lincoln, NE, USA). Blots were 
imaged on the Li-Cor Odyssey CLx Imaging System (LiCor Biosciences, Lincoln, NE, USA) and 
quantified using ImageJ (US National Institutes of Health, Bethesda, MD, USA). 
2.2.6 LogRAi bias calculations 
For all in vitro assays described here, data was normalized to the maximal response of 10µM 
reference agonist U69,593 run at the same time. For [35S]GTPγS, β-arrestin-2, and ERK1/2 
phosphorylation assays, dose response curves were determined using nonlinear regression in 
Graphpad Prism 7 (GraphPad Software, San Diego, CA, USA) and EC50 and Emax values are 
presented with standard error. LogRAi values were calculated as described in Ehlert, 200568 and 
200869 [reviewed with other methods of bias analysis in Kenakin and Christopoulos 2013],70 as 
the LogRAi = log(Emax/EC50). This value is analogous to the transduction factor calculated from 
the operational model of partial agonism,57 as long as the slope factor of the dose-response curve 
is 1.  
In certain instances of very low maximal efficacy, competitive model analysis was 
performed as described in Stahl et al., 2015 in Graphpad Prism 771. These cases are shown in 
Figures 3.3 and 4.2. Normal dose-response data was used for each test compound, as well as 
dose-response data from the test compound in competition with 300nM U69,593. The dose-
response curve of U69,593 was used for reference agonist data. 
For each of these specific instances, the data was fit to the equations below. Here, 
“Bottom” and “Top” refer to the minimum and maximum stimulation in the data set, as a 
percentage of maximal U69,593 stimulation. This is the same units as the output, Y. The LogK 
value is the dissociation constant of the ligand, either reference or test. LogR is the transduction 
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coefficient of the reference ligand. 57 LogRA is the ratio of transduction coefficients of the test 
ligand and the reference ligand. In these equations, X is the concentration of the test ligand, 
while A is the concentration of the reference ligand (held constant in the assays where the test 
ligand is treated as an antagonist). Finally, n is the transducer slope factor which was held to 1 
for analysis. For the β-arrestin-2 and ERK1/2 assays, the U69,593 curve was first fit to the 
reference ligand equation. These parameters were then used to fit the data from the test ligand 
both using the agonist and antagonist equations. Initial parameters and constraints were held as 
described in Stahl et al. 2015.71  
Reference ligand:  
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 + 𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚1 + (1 + 10./01234567810./912345678 ); 
Test ligand as an agonist: 
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 + 𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚1 + (1 + 10(/01234<6=<)10(/9123>9123>?) ); 
 
Test ligand as an antagonist:  
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 + 𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚1 + (1 + 10.?012345678	 + 	10(/0	1234<6=<)10(?9123A) + 	10(/9123>9123>?) ); 
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2.3 Biochemical studies and imaging 
2.3.1 Stable-isotope labelling in cell culture (SILAC) and immunoprecipitation 
HEK 293 cells expressing a KOR tagged with an N-terminal FLAG sequence (DYKDDDDK) 
were grown to confluence in 10cm dishes, in DMEM media containing light or heavy  amino acids 
(15N Lysine and Arginine) (all media from SILAC Protein Quantitation Kit (Trypsin), DMEM, 
ThermoFisher, Waltham, MA, USA). Cells were grown until cells in heavy media had at least 95% 
heavy amino acid incorporation. For immunoprecipitations, cells were lysed in lysis buffer (10% 
v/v glycerol, 75mM Tris pH 7.4, 2mM EDTA, 0.5% v/v digitonin) with PhosSTOP phosphotase 
inhibitor  and cOmplete mini EDTA-free protease inhibitor cocktails (Sigma Aldrich, St Louis, 
MO, USA) and membranes lysed by passage through a 25 gauge needle and subsequent incubation 
and centrifugation. For SILAC experiments, cell lysates were mixed together and incubated with 
Anti-FLAG M2 agarose beads (Anti-FLAG M2 Affinity Gel, Sigma, St. Louis, MO, USA) 
overnight. Beads were washed with ice-cold lysis buffer (0.1% v/v digitonin) and proteins were 
eluted with 1X LDS sample buffer.  
2.3.2 Mass spectrometry analysis 
Samples were run on Bis-Tris protein gels and gel samples were subjected to in-gel tryptic 
digestion.72 The resulting peptides were extracted and purified, analyzed by LCMS using a 
Thermo Orbitrap Fusion Lumos mass spectrometer, with a Thermo Easy-nLC 1200 HPLC and a 
Thermo Easy-Spray electrospray source (ThermoFisher, Waltham, MA, USA). Identification and 
quantification of proteins was performed by searching against a human protein sequence 
database with the MaxQuant software (version 1.2.2.5).73  
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2.3.3 Immunofluorescent sample preparation and imaging 
Coverslips or plastic-bottomed 96-well plates were coated in poly-D-lysine, and HEK cells 
expressing a N-terminal GFP-tagged KOR were plated and grown to 80% confluence. Cells were 
then serum starved for 16-24 hours and cells were treated with the appropriate concentration of 
drug in serum-free media for 1 hour. Cells were fixed and permeabilized with ice-cold methanol, 
and blocked for at least 1 hour in Tris Licor Blocking Buffer (LiCor Biosceinces, Lincoln, NE, 
USA). Cells were stained with pan-14-3-3 primary (14-3-3 (pan) Antibody 8312, 1:50, Cell 
Signaling Technology, Danvers, MA) and Alexa-647 secondary (1:500, Thermo Fisher 
Scientific, Waltham, MA, USA) and subsequently with DAPI (Sigma Aldrich, St Louis, MO) for 
nuclear visualization. If coverslips were used, coverslips were mounted on slides using ProLong 
Diamond Antifade Mountant (Invitrogen, Eugene, OR, USA). Coverslip images (Figure 4.12) 
were taken using an Olymbus IX71 spinning disk microscope. 96-well plates were imaged using 
LSM 780 laser scanning confocal microscopy. Z-stacks from confocal microscopy were 
deconvoluted using Autoquant software (Media Cybernetics, Rockville, MD, USA) and nuclear 
localization was quantified using Imaris (Oxford Instruments, Abingdon, UK).  
2.4 Animal studies 
2.4.1 Animals 
Male C57BL6 mice (9-13 weeks, 20-30g, Charles River Laboratories, Wilmington, MA, USA) 
were used in all studies. Mice were housed, four to a cage, in sound attenuated chambers with 
individual light controls, in stress-minimized rooms, with a reverse 12 hour light/dark cycle, and 
food and water were provided ad libitum. All animals were housed for at least one week, with 
daily handling, prior to studies. Animals were housed and euthanized in a manner approved by 
The Rockefeller University Institutional Animal Care and Use Committee. 
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2.4.2 Prolactin release 
Mice were injected intraperitoneally with KOR agonists in saline (U50,488 and nalfurafine) or a 
vehicle of 10% v/v ethanol, 10% v/v Tween-80 and 80% distilled-deionized water (BPHA, 
MCBPHA, MCPPHA) 30 minutes prior to sampling. LY2444296 or vehicle pretreatment, if 
applicable, was given by intraperitoneal injection 60 minutes prior to sampling. Trunk blood was 
collected by rapid decapitation, followed within 2 hours by preparation of serum. Serum 
prolactin levels were determined using a commercially available enzyme-linked immunoassay 
(AbCam, Cambridge, UK) following dilution of serum 5-fold in assay buffer. 
2.4.3 Rotarod Assay 
Rotarod experiments were conducted with mice using a dedicated rodent rotarod apparatus, with 
up to five animals tested concurrently (IITC Life Science, Woodland Hills, CA, USA). Rotarod 
rotation rate began at 3 rotations per minute, and ramped to 30 rotations per minute over the 
course of 300 seconds, at which time the assay was terminated and animals returned to their 
home cage. Animals were acclimated to the rotarod on at least two occasions prior to the day of 
the test. On the day of the test, baseline times for each animal to fall off the rotarod were 
recorded. Animals that failed to remain on the rotarod for at least 150 seconds during baseline 
testing were removed from the analysis. Mice were then injected intraperitoneally with vehicle or 
compound, and rotarod measurements conducted, beginning 0-2 minutes after injection, and then 
subsequently at select time points thereafter. Rotarod performance was calculated as the percent 
of baseline time spent on the rotarod, and Pearson r correlation between rotarod performance and 
in vitro parameters was done using GraphPad Prism 7.0 (GraphPad Software, San Diego, CA, 
USA). 
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2.4.4 Conditioned-place preference and aversion assays 
Mouse place preference chambers had three distinct compartments, separated by 
removable doors (ENV-3013; Med Associates, St. Albens, VT, USA). The central chamber had a 
solid grey floor and grey walls. The larger, black and white compartments had stainless steel rod 
and mesh floors, respectively. Experiments were performed in dimly-lit, sound attenuated 
chambers. All studies used a biased, counterbalanced design. During the pre-conditioning 
session, each animal was placed in the center compartment with the doors between chambers 
open. Time spent in each chamber was recorded for 30 minutes. 
 
Conditioned-place aversion 
For the conditioned-place aversion experiment with BPHA (Figure 5.7), animals were 
assigned their preferred compartment (black or white) from the pre-test as the drug paired 
chamber. Mice received 4 days of conditioning, with two conditioning sessions (AM and PM) 
per day. Mice were counterbalanced for AM or PM drug-paired conditioning sessions, and 
sessions were at least 3 hours apart. During each conditioning session, mice were pretreated with 
an intraperitoneal injection with BPHA (30mg/kg) or vehicle (10% ethanol, 10% Tween-80, 80% 
water). Then, mice were immediately placed in the appropriate chamber (with doors shut) for 30 
minutes (Figure 2.1). After the four conditioning days, the post-test was performed in which 
mice were allowed free access to all chambers and time spent in each chamber was recorded for 
30 minutes.  
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Figure 2.1. Conditioned place aversion assay set-up. Used for Figure 5.7, testing aversion with 
diphenethylamine compound BPHA.  
 
Conditioned-place preference 
For conditioned-place preference experiments (Figures 5.8 and 5.9), as well as aversion 
of nalfurafine and U50,488 (Figures 5.5 and 5.6), animals were assigned their non-preferred 
compartment (black or white) from the pre-test as the drug paired chamber. Mice received two 
days of conditioning, with two conditioning sessions (AM and PM) per day. Mice were 
counterbalanced for AM or PM drug-paired conditioning sessions, and sessions were at least 3 
hours apart. During each conditioning session, mice were pretreated with an intraperitoneal 
injection with KOR agonist (U50,488, nalfurafine or saline) for 15 minutes, before saline or 
cocaine injection. Then, mice were immediately placed in the appropriate chamber (with doors 
shut) for 30 minutes (Figure 2.2). After the two conditioning days, the post-test was performed in 
which mice were allowed free access to all chambers and time spent in each chamber was 
recorded for 30 minutes. 
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Figure 2.2. Conditioned-place preference assay set-up. Used to test the blockade of cocaine 
reward by KOR agonists U50,488 (Figure 5.8) and nalfurafine (Figure 5.9). Also used to test 
aversion caused by KOR agonists U50,488 (Figure 5.5) and nalfurafine (Figure 5.6). 
 
2.4.5 Intravenous cocaine self-administration 
Adult mice (8-10 weeks) were anesthetized with 5% vaporized isoflurane, and maintained on 2-
3% isoflurane for the duration of the surgery. A catheter approximately 6 cm in length was 
inserted into the right jugular vein, up to a silicon ball placed 1.2-1.3 cm from the end of the 
catheter. Starting 48 hours after surgery, catheters were flushed with physiological saline 
containing heparin and the antibiotic gentamicin every other day to maintain catheter patency. 
For the IVSA experiments, mouse self-administration chambers were used inside sound 
attenuating boxes (ENV-307W; Med Associates, St. Albens, VT, USA). Each self-administration 
chamber contained a wall with two small holes, one defined as active and one defined as 
inactive. Mice were tested for 2 hours daily, with infusions of 0.5 mg/kg/infusion cocaine on an 
FR1 schedule following each active nose poke. During infusion, a cue light above the active hole 
was illuminated and then followed by a 20-second “time-out” period during which no infusions 
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could occur. Pretreatment experiments began when mice reached acquisition criteria, between 6-
10 days after IVSA sessions began, depending on the animal. Acquisition criteria were: >70% of 
nose pokes in the active hole and <20% variation across two consecutive days. On each 
pretreatment day, mice were given IP injections of a KOR agonist (U50,488 or nalfurafine) or 
saline immediately before being placed in self-administration chambers. For the antagonist 
blockade experiment (Figure 5.11), mice were pretreated with 3mg/kg LY2444296 or vehicle by 
IP injection, and then given the KOR agonist or saline injections before being immediately 
placed in self-administration chambers (Figure 2.3). Catheter patency was checked weekly by 
infusion of ~30µL ketamine (5mg/mL), and only data from mice that passed this catheter 
patency test (defined as loss of muscle tone within a few seconds after ketamine infusion) were 
included in data analysis.  
 
Figure 2.3. KOR agonist pretreatment set-up for cocaine IVSA  
 
2.4.6 In vivo data analysis 
Analysis of variance (ANOVA) tests were used to assess the effects of drug treatments on in 
vivo endpoints. Post-hoc multiple comparison tests were chosen based on relevant comparisons. 
Dunnett’s post-hoc test was used to compare treatment groups to vehicle or saline control 
groups. Newman-Keuls post-hoc test was used to compare all treatment groups to each other, as 
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was often the case for antagonist pretreatment experiments for KOR specificity. Finally, Sidak’s 
multiple comparison post-hoc test was used in the case of the intravenous self-administration 
experiments, in which there were repeated measures on time.  
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CHAPTER 3. G-PROTEIN VS ARRESTIN BIAS OF KOR LIGANDS 
 
3.1 b-Arrestin-2 and G-protein signaling pathway activation by KOR ligands 
While ligand bias can be measured between any signaling events or effectors downstream 
of an activated GPCR, “bias” most commonly refers to the difference between the receptor-
proximal G-protein and b-arrestin signaling pathways.74 Several studies have examined the 
ability of different KOR agonists to activate both of these signaling pathways, using a variety of 
different cell lines and endpoints. To measure G-protein recruitment to the receptor directly, 
bioluminescence resonance energy transfer (BRET) and radioligand binding assays ([35S]GTPgS) 
are frequently used.66 Importantly, the [35S]GTPgS assay can be carried out in native tissue 
without genetic manipulations – this method has been optimized by the Bohn group to measure 
endogenous G-protein coupling in rodent striatum.66 Second messengers downstream of G-
protein activation, such as the inhibition of cAMP release and increased calcium release, are also 
used to measure G-protein activity downstream of the KOR. Finally, downstream signaling 
pathways such as ERK1/2 have also been used occasionally as proxies for G-protein activation.  
In contrast to G-protein recruitment, heterologous cell lines must be used in BRET or 
enzyme fragment complementation assays to measure b-arrestin recruitment directly, with 
genetically modified versions of one of the isoforms of b-arrestin. Downstream responses such 
as internalization or p38 phosphorylation have also been used to measure arrestin recruitment 
indirectly. 
 In addition to the wide array of endpoints that have been used to measure these signaling 
pathways in the literature, it has also been shown that ligand bias is context-dependent, meaning 
the same ligand can differentially activate signaling pathways depending on the cell line or tissue 
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tested, for many GPCRs including the KOR.75 These factors make it very difficult to compare 
across studies, and to draw any generalizations about the actions of biased ligands at the KOR.  
 The goal of this work, the majority of which was published in ACS Chemical 
Neuroscience in 2019,34 was to compare the G-protein and b-arrestin-2 recruitment of 21, 
structurally diverse KOR ligands (Figure 3.1) in one cellular context. Here, we used the 
PathHunter U2OS hOPRK1 cell line, measuring G-protein signaling using the [35S]GTPgS assay 
and b-arrestin-2 recruitment using the PathHunter DiscoverX enzyme fragment complementation 
assay. By using a single context, we could compare the activity of these ligands within their 
structural classes, and between structural classes.  
 
3.1.1 Diverse KOR agonists tested for signaling properties 
Most studies of the signaling properties of KOR agonists examine individual structural 
classes of ligands, with a few studies investigating larger sets of KOR ligands for specific 
signaling properties.55  In this study, we aimed to examine a wide range of structurally diverse 
ligands for their early, receptor-proximal signaling properties at the KOR in a single cellular 
context. By using such a structurally diverse group of ligands, including the endogenous opioid 
neuropeptide dynorphin A (1-17), we could potentially draw more generalizable conclusions 
about the relationships between in vitro signaling properties and in vivo effects of KOR agonists. 
 First, the endogenous peptide ligand dynorphin A (1-17) was tested (Figure 3.1 A). 
Dynorphin peptides are cleaved from a precursor protein into several different lengths, with 
varying specificity for the opioid receptors. The form tested here, dynorphin A (1-17), is the 
most KOR-specific of the Dynorphin peptides and responsible for the majority of endogenous 
KOR activation.76,77 In addition to dynorphin A (1-17), the other naturally-occurring compound 
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tested here was the natural product salvinorin A (Figure 3.1 A). Salvinorin A is a non-
nitrogenous diterpene that is structurally unrelated to all other opioid ligands, and was recently 
characterized as a potent, selective KOR agonist.30 Like many other KOR agonists, salvinorin A 
has considerable aversive, psychotomimetic and dysphoric properties in clinical and preclinical 
studies.31,78 This discovery led to the development of salvinorin-based derivatives for KOR-
targeted drug discovery. For example, the semi-synthetic analog mesyl salvinorin B, tested here 
as well, was previously characterized in vivo for its improved side-effect profile compared with 
the parent natural product salvinorin A (Figure 3.1 A).79  
 The most extensively-studied group of synthetic, selective KOR agonists are the 
arylacetamide compounds (Figure 3.1 C), based on the structure U50,488.80 There has been 
extensive preclinical and in vitro pharmacology characterizing these compounds, however very 
few additional human studies have been conducted because of the negative side effects identified 
in early studies of arylacetamide agonists in humans, including spiradoline (U62,066E).26–28 
 While the naturally-occurring and arylacetamide groups of compounds are all relatively 
KOR-selective, we also tested several morphinan compounds that are better known for their 
activity at other opioid receptors (Figure 3.1 B). Nalmefene, naltrexone, buprenorphine and 
nalbuphine are all clinically-utilized compounds that are primarily recognized for their MOR 
activity. Nalmefene and naltrexone are MOR antagonists that have been previously studied for 
KOR partial agonism or antagonism.32 Nalmefene is currently approved to treat alcoholism in 
Europe. Naltrexone is approved to treat opioid addiction and alcoholism in the US under the 
brand name Vivitrol, among others. Buprenorphine is also approved to treat opioid addiction, 
however it is a partial agonist at the MOR. Buprenorphine has also been reported to bind to the 
KOR, with reports of both partial agonism and antagonism.81,82 Nalbuphine is also a MOR partial 
 30 
agonist used to treat pain clinically, and has been shown to have partial KOR activity in certain 
signaling pathways.83 All four of these morphinans have shown varying levels of KOR agonism 
for G-protein signaling, but very little activity in b-arrestin-2 recruitment or internalization 
assays previously.  
 The final morphinan compound studied was nalfurafine, which is clinically approved to 
treat pruritus in Japan under the name Remitch. Nalfurafine is a KOR agonist with some MOR 
activity, with ~2-10 fold binding selectivity for KOR over MOR.35 Nalfurafine is notable for its 
very high potency at the KOR – the daily oral dose of Remitch for humans is 2.5µg. There have 
been reports of signaling at both the G-protein and b-arrestin-2 pathways, however 
measurements of ligand bias between the two pathways vary between studies.35,36 One study, for 
example, used downstream signaling kinases ERK1/2 and p38 as readouts for G-protein and b-
arrestin-2 signaling, respectively, to suggest that nalfurafine was biased for G-protein signaling 
over b-arrestin-2 signaling. Other groups have suggested that nalfurafine is unbiased because it 
shows full efficacy in assays for both signaling pathways. 
 In addition to these groups of well-characterized KOR ligands, we also tested two 
recently-described structural classes (Figure 3.1 D and E). The quinoxaline compounds WMS 
0611 (which was first described as a peripherally-restricted KOR agonist) and 0610 by 
Bourgeois, et. al. 2014 and the diphenethylamine family of compounds first described by Spetea, 
et. al. 2012 were also tested. 64,84 BPHA (Compound 5 of Spetea et. al., 2012), MCBPHA 
(HS665 of Spetea et. al., 2012), MCPPHA (Compound 3 of Erli et. al., 2017) and HS666 (Spetea 
et. al., 2017) were further characterized in later studies for G-protein vs arrestin bias, as well as 
other KOR-mediated in vivo endpoints in mice.85–87 Compounds 3G1 and 3G2, which were 
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novel to our 2019 ACSCN study, are structurally related to the diphenethylamines, and included 
in this class as well.34 
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Figure 3.1. Structures of KOR agonists tested 
Structures are arranged according to compound classes: A. the endogenous ligand dynorphin 
A(1-17), the natural product salvinorin A and the derivative mesyl salvinorin B; B. morphinan 
compounds; C. arylacetamide compounds; D. quinoxaline compounds; E. diphenethylamine 
compounds.  
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3.1.2 b-Arrestin-2 enzyme fragment complementation by KOR ligands in DiscoverX U2OS 
Cells 
We tested each compound for b-arrestin-2 recruitment using the DiscoverX PathHunter 
enzyme fragment complementation (ECF) assay system. The DiscoverX PathHunter U2OS cell 
line used expressed an enzyme-fragment-linked human KOR, as well as an enzyme-fragment-
linked b-arrestin-2, used for signal detection. All responses were blocked with KOR-selective 
antagonist nor-Binaltorphimine (norBNI) to determine KOR-selectivity. In Figure 3.2, potency 
(EC50) and maximal efficacy (Emax) values are given as averages of 3 separate experiments, with 
4 technical replicates per experiment alongside representative dose-response curves. The 
maximal efficacy of all other compounds was compared to the maximal efficacy of a 
concurrently run U69,593 dose-response curve, as U69,593 was used as the reference agonist in 
these experiments. The tables also include a LogRAiArr value, described in further detail in 
Subsection 3.2.1, that compares activity of each ligand to the reference agonist U69,593. 
 In this assay, the reference agonist U69,593 robustly recruited b-arrestin-2, with a mean 
EC50 of 683nM (Figure 3.2). The endogenous ligand dynorphin A (1-17) was more potent than 
the reference agonist, as was the natural product salvinorin A. Mesyl salvinorin B, a derivate of 
salvinorin A, had similar activity to that of the reference agonist (Figure 3.2 A).  
 The other arylacetamide compounds, which are structurally related to the reference 
agonist U69,593 (Figure 3.1 C), all showed robust b-arrestin-2 recruitment with higher potencies 
and similar maximal efficacies compared with U69,593 (Figure 3.2). The compound GR89,696 
was the most potent compound tested in this assay, with an average EC50 of 13.7nM.  
The morphinan compounds, by contrast, overall showed very little b-arrestin-2 
recruitment (Figure 3.2 B). Nalbuphine showed very modest b-arrestin-2 recruitment, with an 
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EC50 of over 4000nM and only 26% maximal efficacy. Nalmefene, naltrexone and 
buprenorphine did not demonstrate any measurable b-arrestin-2 recruitment in this assay (Figure 
3.2 B). Dose-response curves of these compounds were tested against a steady concentration of 
300nM U69,593 in this assay, in order to determine their ability to antagonize b-arrestin-2 
recruitment by the reference agonist. In this paradigm, nalmefene, naltrexone and buprenorphine 
were potent antagonists of this signaling pathway (Figure 3.3). The exception in the morphinan 
class of compounds was nalfurafine, which had very robust b-arrestin-2 recruitment. Nalfurafine 
had a similar maximal efficacy to the reference agonist U69,593 and greater potency with a mean 
EC50 of 38.3nM (Figure 3.2 B).  
Overall, the more recently described quinoxaline and diphenethylamine compounds did 
not show much b-arrestin-2 recruitment (Figure 3.2 D, E). WMS 0611 had more activity in this 
assay than the closely-related WMS 0610, with average EC50 values of 28µM and 4.3µM, 
respectively. The diphenethylamines HS666 and BPHA were antagonists in this assay (Figure 
3.2 E), with full blockade but relatively large IC50 values (Figure 3.3). The remaining 
diphenethylamines (MCBPHA, MCPPHA, 3G1 and 3G2) were partial agonists for b-arrestin-2 
recruitment (Figure 3.2 E). 
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Figure 3.2. b-Arrestin-2 EFC by KOR ligands and representative dose-response curves 
Figures are arranged by structural class: (A) the endogenous ligand dynorphin A (1-17), the 
natural product salvinorin A and its derivative mesyl salvinorin B, (B) morphinan compounds, 
(C) arylacetamide compounds, (D) quinoxaline compounds and (E) diphenethylamine 
compounds. Emax values were calculated as the percentage of maximum U69,593 response from a 
concurrent U69,593 dose-response curve. Average EC50 and Emax values are represented as 
averages of 3 separate experiments with 4 replicates per experiment (±SEM). For compounds 
with low Emax values, data from the antagonist curves were fit to the operational model of partial 
agonism to calculate LogRAi values (*). Representative dose-response curves are shown 
alongside a representative U69,593 dose-response curve, in black in each graph. U69,593 
stimulation was between 160 and 250% above baseline (800-2000 CUs). 
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Figure 3.3. Blockade of U69,593-induced b-Arrestin-2 EFC by KOR ligands and 
representative dose-response curves. Compounds from (A) morphinan and (B) 
diphenethylamine classes of compounds with low Emax values were tested as antagonists to block 
arrestin enzyme fragment complementation by 300nM U69,593. Maximum inhibition values 
were calculated as the percentage of 300nM U60,593 response. Average IC50 and Max Inhibition 
values are represented as averages of 3 separate experiments with 4 replicates per experiment 
(±SEM). 
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3.1.3 [35S]GTPgS binding by KOR ligands in DiscoverX U2OS cells 
Each compound was tested for G-protein activation using the [35S]GTPgS radioligand 
binding assay. This assay was done using membranes prepared from the same DiscoverX 
PathHunter U2OS cell line used for the b-arrestin-2 recruitment assay, in order to determine 
differential signaling mechanisms in the same context. All responses were antagonized with 
norBNI to determine KOR-selectivity, as this assay will measure any G-protein activity in the 
cell line. In Figure 3.4, potency (EC50) and maximal efficacy (Emax) values are given as averages 
of 3 separate experiments, with 4 technical replicates per experiment alongside representative 
dose-response curves. The tables also include a LogRAiG value, described in further detail in 
Subsection 3.2.1, that compares activity of each ligand to the reference agonist U69,593. 
 The reference agonist U69,593 caused robust G-protein activation in this assay, with an 
average EC50 value of 3.3nM (Figure 3.4). Many compounds were more potent than U69,593 in 
this assay, however. Dynorphin A (1-17) was very potent for G-protein activation, with an 
average EC50 of 0.04nM (Figure 3.4 A). Both salvinorin A and mesyl salvinorin B were more 
potent than the reference agonist as well, however all of these compounds had maximal 
efficacies below 100%.  
 The arylacetamide compounds showed robust G-protein activation as well, with EC50 
values ranging from 0.03nM to 0.6nM (Figure 3.4 C). The arylacetamide compound GR89,696 
was the most potent compound tested in this assay, as it was in the b-arrestin-2 recruitment 
assay. The morphinan compounds also exhibited potent activity in this assay, and had maximal 
efficacy values ranging from 44.5% (nalbuphine) to 84.3% (nalfurafine) (Figure 3.4 B).  
 The quinoxaline and diphenethylamine compounds had variable G-protein activity 
downstream of the KOR, despite the structural similarity within groups (Figures 3.1 D, E). WMS 
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0611 was ~4-fold more potent than WMS 0610 for G-protein activation. EC50 values for the 
diphenethylamine series of compounds ranged from 0.5nM for MCPPHA to 22.7nM for HS666, 
with all compounds having similar maximal efficacies (75-87%) (Figure 3.4 E).  
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Figure 3.4. [35S]GTPgS binding by KOR ligands and representative dose-response curves 
Figures are arranged by structural class: (A) the endogenous ligand dynorphin A (1-17), the 
natural product salvinorin A and derivative mesyl salvinorin B, (B) morphinan compounds, (C) 
arylacetamide compounds, (D) quinoxaline compounds and (E) diphenethylamine compounds. 
Average EC50 and Emax values are presented in tables as averages of 3 separate experiments with 
4 replicates per experiment (±SEM). Emax values were calculated as the percentage of maximum 
U69,593 response from a concurrent U69,593 dose-response curve. LogRAi values were 
estimated from these average EC50 and Emax values. Representative dose-response curves are 
shown alongside a representative U69,593 dose-response curve, in black in each graph. U69,593 
stimulation was between 35 and 70% above baseline (2000-8000 DPM). 
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3.1.4 GTPg35S binding by KOR ligands in mouse striatum tissue 
While measuring arrestin recruitment directly requires heterologous cell lines, G-protein 
binding can be measured directly in native tissue. In order to examine G-protein signaling in a 
more physiologically-relevant context, we also investigated G-protein signaling in mouse striatal 
tissue, where there is dense KOR expression.88 Mouse caudate putamen and nucleus accumbens 
were dissected and homogenized, and membranes were prepared for radioligand binding assays 
as described in Zhou, et. al. 2015.66 
 First, we optimized the preparation of the striatal membranes for KOR binding, and 
measured G-protein binding in the mouse striatum using the [35S]GTPgS assay. The full 
reference agonist U69,593 robustly stimulated G-protein binding in the mouse striatum samples 
(Figure 3.5 A), and this effect was fully blocked by the KOR-selective antagonist norBNI 
(Figure 3.5 B). Nalmefene, which has been previously shown to be a partial agonist at the KOR, 
showed less than 50% G-protein binding compared to U69,593 in the mouse striatum (Figure 3.5 
B). EC50 values for both compounds were higher than in U2OS cells, but consistent in their rank 
order (Figure 3.4 B, 3.6 A). 
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Figure 3.5. [35S]GTPgS binding in mouse striatum tissue 
Mouse striatum tissue was homogenized and incubated with 10nM [35S]GTPgS and increasing 
concentrations of test compounds. Emax values are shown here as a percentage of max U69,593 
response (2000-8000 DPM). (A) Dose-response curve for U6,593 had an EC50 of 34.7nM and 
nalmefene had an EC50 of 3.1nM. (B) Emax values alone are shown for co-treatment of tissue with 
10µM U69,593 and 10µM antagonist norBNI and treatment of tissue with 20µM nalmefene.  
 
3.1.5 Discussion 
Many studies have pointed out the caveats of studying GPCR signaling pathways using 
heterologous cell systems. Unfortunately, it is currently necessary to use modified receptor and 
arrestin proteins in order to directly measure arrestin recruitment. In addition to the enzyme 
complementation assay used here, other methods of measuring arrestin recruitment also utilize 
fusion proteins, such as FRET and BRET. The less direct methods of measuring arrestin activity, 
such as internalization or p38 phosphorylation, do not require modified proteins, however, they 
do not account for the potential contributions of other signaling pathways. 
In addition to the issue of modified protein structure and function, there is also recent 
evidence that GRK2 expression levels affect measurements of arrestin signaling at the mu opioid 
receptor,89 including in the DiscoverX PathHunter assay.45 Specifically lower levels of GRK2 
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expression were shown to mask partial agonism by decreasing overall signal. It is possible that 
the lack of GRK2 expression in the U2OS cells used here is leading us to underestimate the 
amount of arrestin recruitment caused by some agonists, such as the morphinan compounds that 
showed almost no measurable arrestin recruitment (Figure 3.2 B). However, our results are 
consistent with previous studies of morphinan compounds using other methods to assess arrestin 
activation. For example, nalbuphine was shown to cause minimal internalization,54 and 
buprenorphine also demonstrated minimal arrestin recruitment in a BRET assay that included 
GRK2 co-expression.81  
Using the U2OS DiscoverX PathHunter cell line for the [35S]GTPγS assay, we found an 
unusually high level of G-protein coupling compared to previous studies. In particular, the 
morphinan series of compounds was found to have higher Emax values in the [35S]GTPgS assay 
than expected – most published reports give maximal efficacy of less than 50% (compared to 
reference agonists) for compounds nalmefene, naltrexone and nalbuphine, where we 
demonstrated maximal efficacy between 70-80% compared to the full agonist U69,593 (Figure 
3.4 B). This assay has been reported to be particularly susceptible to cellular context, because of 
different coupling levels for different G-proteins,81 as well as a saturation effect if levels of 
receptor expression are too high. While the goal of this study was to investigate both signaling 
pathways within the same cell line, in future studies it would be beneficial to measure G-protein 
signaling directly in disease-relevant tissue. 
To investigate G-protein activation in a more physiologically-relevant context, we tested 
several compounds for [35S]GTPγS binding in mouse striatal tissue. This assay showed similar 
levels of [35S]GTPγS binding for the reference agonist U69,593, and demonstrated lower 
efficacy agonism for the morphinan compound nalmefene that is more consistent with both 
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previous literature and known effects in humans (Figure 3.6 B). Previous studies have shown that 
nalmefene is a partial KOR agonist in humans, using the serum prolactin as a biomarker for 
KOR activation.32 Additionally, data from humans in clinical trials and post-marketing data from 
the use of nalmefene to treat alcohol addiction indicates that nalmefene does not cause side 
effects like hallucinations or psychotomimesis,90 while full KOR agonists tested in humans, such 
as spiradoline (U62,066E) and salvinorin A do.28,31 Together with in vitro G-protein activation 
data from other cell lines and studies, these data indicate that nalmefene is likely acting as a 
partial KOR agonist in the therapeutically-relevant setting, and the data from the striatal tissue 
[35S]GTPγS experiment more accurately models that setting than the [35S]GTPγS data from the 
U2OS cells (Figures 3.4 B, 3.6 B). While this system is promising for measuring G-protein 
binding, it is still relatively inconsistent. Additional troubleshooting and optimization are 
required, and then additional compounds can be examined in the future. 
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3.2 KOR ligand bias and relationships between in vitro metrics and in vivo activity 
In order to quantify ligand bias for these compounds in our U2OS cell system, we first 
needed to control for systemic factors. For example, directly comparing the EC50 of a compound 
in the [35S]GTPgS assay and the b-arrestin-2 assay will not give a good measurement of bias 
because of differences in assay kinetics. To control for this kind of “system bias”, we chose to 
use U69,593 as our reference ligand to run alongside all the other KOR agonists tested here. 
Each ligand could then be compared against the reference ligand, to control for assay-specific 
factors. All measurements of ligand bias are dependent on the reference agonist chosen, and this 
is another part of the “context” that is important to describe when describing a biased agonist.   
 For studies of the KOR, several different ligands have been used as the reference. Several 
groups have used dynorphin A (1-17), because it is the major endogenous neuropeptide.54 We 
chose U69,593 as the reference agonist because it has been widely-characterized in many 
different labs as a full, unbiased agonist at the KOR with full activation of both the G-protein and 
b-arrestin-2 signaling pathways using several different assays.  
 To compare the activity of a test ligand to the reference ligand, we used a method based 
on the operational model of partial agonism. First described by Black and Leff in the 1980’s, this 
model uses dose response data from both the test agonist and the reference agonist to calculate a 
measurement of intrinsic relative activity (RAi).69 This metric takes into account both the 
potency and maximal efficacy of the test agonist, and is presented here as the LogRAi. While 
this metric can be calculated from fitting dose-response data directly to the operational model, 
when the Hill slope is equal to 1 it can be estimated using the Emax and EC50 values of the dose-
response curve. For compounds that had very low intrinsic activity in a given assay, and 
therefore could not be fit to a traditional sigmoidal dose-response curve, we used a modified 
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version of the operational model (described by Stahl at al. 2015)71 to directly calculate the 
LogRAi value from dose-response data. LogRAi values were calculated for each compound for 
both G-protein and arrestin assays, and compared to quantify ligand bias between the two 
signaling pathways (DLogRAi).  
  We could then use this composite DLogRAi metric, as well as metrics from both the in 
vitro assays alone, to investigate relationships between agonist activity in vitro and in vivo. 
Because of the use of heterologous cell lines and the context-dependent nature of many of these 
signaling pathways, it is difficult to use in vitro activity to predict in vivo behaviors. This is 
critical, however, for drug discovery efforts. The Bohn lab recently demonstrated that a 
calculated composite “bias factor” for MOR agonists tested in vitro correlated with the 
therapeutic window between antinociceptive effects and respiratory depression in mice.46 
Similarly, the Van Rijn lab demonstrated that efficacy measured in an arrestin assay correlated 
with increased alcohol intake caused by DOR activation in mice.91 Both of these studies 
demonstrate how these in vitro-in vivo relationships could help to improve drug discovery efforts 
for safer and more effective opioid receptor agonists. In these studies, we looked at the 
relationship between KOR agonist activity in vitro and sedation in mice, measured by the rotarod 
assay. 
 
3.2.1 Quantifying ligand activity bias with intrinsic relative activity metric 
To compare each compound to U69,593, we calculated the LogRAiG and LogRAiArr, 
which give a quantitative comparison of the activity of each compound to the reference agonist 
U69,593 in the given assay (Figures 3.2 and 3.3). By definition the reference agonist U69,593 
has a LogRAi of 0. A value larger than 0 indicates a compound that has higher relative intrinsic 
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activity in that assay, and any value below 0 indicates a compound that has less activity relative 
compared to the reference agonist in that assay, as seen in Figures 3.2 and 3.3. In certain cases 
where the maximal efficacy was very low in the b-arrestin-2 recruitment assay, a dose-response 
curve could not be fit to the data and no Emax and EC50 value was available for LogRAi 
estimation. This was the case for several morphinan compounds, as well as the 
diphenethylamines HS666 and BPHA (Figure 3.3). In these cases, additional dose-response 
curves of the compounds were tested in the presence of a steady concentration of U69,593 to 
determine the antagonist properties of the compounds. These antagonist curves were then fit to a 
modified version of the operational model of partial agonism and the LogRAi values were 
calculated from these parameters.71  
 In order to compare the bias of a compound between the two signaling pathway assays, 
the DLogRAiG-Arr was calculated as (DLogRAiG-Arr = LogRAiG  - LogRAiArr) (Figure 3.6). 
Almost all the compounds tested were G-protein biased in this system compared to the reference 
agonist U69,593. Salvinorin A and its derivative mesyl salvinorin B were the most “balanced” 
compounds tested, and most of the other arylacetamide compounds were also relatively unbiased 
(Figure 3.6). The majority of the morphinan compounds, on the other hand, exhibited very robust 
G-protein bias. The exception in this structural class was nalfurafine, which was the only 
compound we tested that was biased for b-arrestin-2 recruitment over G-protein signaling (with a 
negative (DLogRAiG-Arr value) (Figure 3.6). Both groups of recently-described KOR agonists, the 
quinoxalines and the diphenethylamines, were G-protein biased with varying degrees of bias.  
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Figure 3.6. DLogRAi measurements of bias for KOR ligands 
The DLogRAiG-Arr values were calculated (LogRAiG - LogRAiArr) to quantify ligand bias for each 
compound compared to the reference agonist U69,593. Positive DLogRAiG-Arr values indicate 
bias for G-protein signaling over b-arrestin-2 signaling, while negative DLogRAiG-Arr values 
indicate bias for b-arrestin-2 signaling over G-protein signaling, relative to the reference agonist 
U69,593. DLogRAiG-Arr values were calculated using the average EC50 and Emax as described in 
the methods from three separate experiments, and are shown here plus/minus combined standard 
deviations.  
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3.2.2 Correlation between ligand activity in vitro and in vivo sedation behavior 
The goal of quantifying ligand activity in vitro was to develop a method to determine 
which compounds have the desired therapeutic properties. In order to better understand which in 
vitro measurements of ligand activity best modeled in vivo responses, we compared different in 
vitro metrics for both the G-protein and b-arrestin-2 signaling assays to an in vivo measurement 
of sedation / motor incoordination. 
 To assess the undesirable effects of sedation / motor incoordination, we used the rotarod 
assay. In this assay, C57BLJ6 mice were trained to run on an accelerating rod and their baseline 
ability to stay on the rod as it accelerates was recorded. Mice were then injected intraperitoneally 
with drug and tested for rotarod performance. Ligands that caused sedation or motor 
incoordination led to decreased rotarod performance compared to baseline (mice fell off of the 
rod earlier than they had in their baseline run). We tested high doses of these compounds in this 
assay, both to assess the maximum possible rotarod effect and to minimize the effect of differing 
pharmacokinetic properties between compounds.  
 The maximum effect of most compounds tested occurred at 30 minutes post-injection. 
Results are presented as the percentage of baseline rotarod performance (e.g. 100% of baseline 
performance is no impairment) at this 30 minute timepoint. Consistent with previous studies, we 
found that the arylacetamide compound U50,488 was very sedative at the high dose of 30mg/kg 
(Figure 3.7). The morphinan compound nalfurafine was also very sedative, and more potent than 
U50,488, with a similar effect at only 3mg/kg. Most of the diphenethylamine compounds tested 
(MCBPHA, MCPPHA, 3G1 and 3G2) had a partial effect in this assay, with rotarod performance 
between 54% and 70% of baseline performance (Figure 3.7). The diphenethylamine BPHA, on 
the other hand, did not cause any measurable rotorod impairment (Figure 3.7). The morphinan 
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compounds nalmefene and nalbuphine similarly did not cause any measurable rotarod 
impairment, with rotarod performance close to 100% that of baseline testing (Figure 3.7).  
 This maximum effect on the rotarod test was then compared to several different in vitro 
measurements of ligand activity using Pearson r correlation (Figure 3.8). There was a significant 
correlation (r = -0.97, p<0.001) between the Emax measured in the b-arrestin-2 recruitment assay 
and the maximum effect on the rotarod test (Figure 3.8 A). However, there was no significant 
correlation between the Emax measured in the [35S]GTPgS assay and the rotarod performance 
(Figure 3.8 C). Likewise, there was no correlation between the EC50 in the [35S]GTPgS assay or 
the LogRAiG measurement of relative activity (Figure 3.8 D). Because so many of the 
compounds tested in the b-arrestin-2 recruitment assay had very little intrinsic activity, the 
correlation for the arrestin EC50 data is not shown. From the limited data available, there was no 
significant correlation between arrestin EC50 and rotarod sedation. However, there was a 
significant correlation (r = -0.96, p < 0.0001) between the LogRAiArr and rotarod performance 
(Figure 3.8 B). Finally, there was a weaker, but significant, correlation (r = -0.76, p<0.05) 
between the DLogRAiG-Arr  measurement of ligand bias and rotarod performance (Figure 3.8 F). 
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Figure 3.7. Rotarod sedation by select KOR ligands 
Rotarod performance is reported here as the percentage of baseline performance 30 minutes after 
intraperitoneal injection of 30mg/kg compound (except nalfurafine, at 3mg/kg). N = 7-8 animals 
per group.  
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Figure 3.8. Correlation of in vitro metrics with rotarod sedation 
Pearson r correlations comparing in vitro measurements (X axis) with rotarod performance were 
calculated for (A) b-arrestin-2 Emax, (B) b-arrestin-2 LogRAi, (C) G-protein Emax, (C) G-protein 
EC50, (E) G-protein Emax, and (F) the DLogRAiG-Arr measurement of ligand bias. Both 
measurements of b-arrestin-2 activity (A and B) as well as the measurement of ligand bias (F) 
correlated significantly with rotarod activity.  
 
3.2.3 Discussion 
Using the U2OS DiscoverX PathHunter cell line for both the [35S]GTPgS and b-arrestin 
signaling pathway assays and U69,593 as the reference agonist, we found the vast majority of the 
compounds we tested to be G-protein biased agonists (Figure 3.6). Even compounds that had 
previously been reported to be relatively unbiased compared to U69,593, such as salvinorin A, 
were slightly G-protein biased in this system, as well as the other arylacetamide compounds that 
are structurally very similar to U69,593. This indicates that U69,593 was uniquely effective at 
recruiting b-arrestin in this system compared to the other agonists, however it also suggests that 
our system was particularly sensitive to G-protein coupling over arrestin recruitment. 
 We found the majority of the morphinan compounds, namely nalbuphine, nalmefene, 
naltrexone and buprenorphine, to be very G-protein biased (Figure 3.6). This is consistent with 
previous reports of their ligand bias in these signaling pathways, even using other cell lines and 
other endpoints.32,81 A study of ligand bias for MOR agonists demonstrated that measurements of 
ligand bias are most resilient to differing context in the cases of “extreme” bias, when there is 
little measurable activity at one of the signaling pathways.46 Nalfurafine, on the other hand, was 
found to be arrestin-biased by our calculations (Figure 3.6), while it has been described as both 
unbiased and G-protein biased using other cell lines and other end-points for G-protein and 
arrestin signaling. In our hands nalfurafine had similar potency for G-protein signaling to the 
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reference agonist U69,593. In the b-arrestin-2 recruitment assay, however, nalfurafine was ~20-
fold more potent than the reference agonist. This high potency in the b-arrestin-2 recruitment 
assay then translated to a negative DLogRAiG-Arr value, which indicated arrestin-bias in our 
system. Further investigation into the signaling properties of nalfurafine could help to explain its 
unique behavioral profile compared to other KOR agonists.   
 The diphenethylamine series of compounds had varied bias profiles, with the compound 
BPHA having a larger DLogRAiG-Arr value (indicating G-protein bias) while the remaining 
compounds had DLogRAiG-Arr values closer to zero (Figure 3.6). Interestingly, BPHA was the 
only diphenethylamine compound tested that had a non-cyclic side chain off of the central 
amine, suggesting an important role for this part of the molecule in determining arrestin 
recruitment (Figure 3.1 E). WMS 0610 and WMS 0611 differ only in one phenyl ring (Figure 3.1 
D), however WMS 0610 was significantly more G-protein biased than WMS 0611 (Figure 3.6). 
Data like these can be used in the future to help drive structure-activity relationship studies of 
KOR ligands, to improve drug discovery efforts.  
 Finally, we investigated the relationships between the in vitro measurements and 
quantifications of the activity of these ligands and their actual effect in an in vivo assay of 
sedation / motor incoordination in mice. We found that measurements of arrestin recruitment 
activity, including the maximum efficacy (Emax) and the LogRAi (which takes into account both 
Emax and EC50) were significantly correlated with the maximum effect in the rotarod assay 
(Figure 3.8 A, B). None of the measurements of G-protein activity, on the other hand, correlated 
with this rotarod effect (Figure 3.8 C, D, E). This supports the hypothesis generated by previous 
studies of single structural classes of biased KOR ligands that b-arrestin-2 recruitment is 
involved in KOR-mediated sedation as measured by the rotarod assay.51,52,86 While the 
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quantification of overall G-protein vs arrestin bias (DLogRAiG-Arr) did have a significant 
correlation (Figure 3.8 F), it was weaker than the arrestin correlations alone. Together, these data 
suggest that a G-protein biased agonist at the KOR could be more likely to have an acceptable 
therapeutic “window”, due to a lack of sedative side effects even at high doses. 
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CHAPTER 4. OTHER SIGNALING PATHWAYS DOWNSTREAM OF THE KOR 
 
4.1 ERK1/2 and mTOR signaling pathway activation by KOR ligands 
In addition to profiling the G-protein and b-arrestin-2 recruitment of the ligands that target 
the KOR, there are several other signaling pathways that have been shown to be important for 
KOR activity and specifically addiction-related behaviors. Various mitogen-activated-protein 
kinases (MAPK), for example, have been shown to be phosphorylated by KOR agonist activity, 
including extracellular-related kinases 1 and 2 (ERK1/2).92 ERK1/2 has also been shown to be 
important for the incubation of cocaine craving, and other drug-related behaviors.93 There have 
been varying results in the literature linking ERK1/2 phosphorylation at different time points to 
either G-protein or arrestin signaling, however it is difficult to draw larger generalizations across 
these studies because of the diverse array of cell lines, time points and KOR agonists used. 
Importantly, a study of a series of novel triazole KOR agonists demonstrated that ERK1/2 
phosphorylation can be modulated independently of G-protein vs arrestin bias.62 This was one of 
the first studies to suggest that downstream signaling pathways like ERK1/2 should be tested 
independently of G-protein and arrestin pathways, and that the pharmacological profile of KOR 
agonists had the potential for much more diversity than was previously believed.  
The mTOR signaling pathway is now known to be important for integrating cellular 
signaling in the central nervous system.94 More recently, the mTOR pathway has been shown to 
be important for KOR-mediated behavior, specifically aversion.36,39 It is unclear, however, if and 
how mTOR activation is related to G-protein or arrestin signaling pathways. In this study we 
tested the same set of diverse KOR agonists (Figure 3.1) for ERK1/2 phosphorylation and 
mTOR pathway activation and compared their activity in these pathways to their activity in the 
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early signaling pathways (G-protein and arrestin) tested in Chapter 1. This ERK1/2 and mTOR 
signaling pathway data was also included in the 2019 publication with G-protein and arrestin 
signaling data for these compounds.34 
 
4.1.1 ERK1/2 phosphorylation by KOR ligands in HEK cells  
Diverse KOR agonists were tested for ERK1/2 phosphorylation in HEK cells using in-
cell western blotting. Figure 4.1 shows representative dose-response curves, with potency and 
maximal efficacy values as averages of 3 replicates per experiment, as well as the LogRAiERK 
value comparing the activity of each ligand to the reference ligand U69,593. In the case of very 
low intrinsic activity, compounds were tested as antagonists against a steady concentration of the 
reference agonist (300nM U69,593) and that data was used to calculate the LogRAiERK value 
(Figure 4.2). 
Within the class of naturally-occurring compounds and their derivatives, both Salvinorin 
A and mesyl salvinorin B had increased potency and maximum efficacy for ERK1/2 
phosphorylation compared to the reference agonist U69,593, shown in black on every graph. 
U69,593 had an EC50 of 113.9nM in this assay, and salvinorin A and mesyl salvinorin B had 
EC50s of 20.3 and 37.3nM, respectively (Figure 4.1 A). Dynorphin A(1-17), however, had 
decreased activity with respect to the reference agonist with a potency of 710nM.  
Generally, the morphinan compounds had very little activity for ERK1/2 
phosphorylation, and buprenorphine was able to block U69,593-induced ERK1/2 
phosphorylation (Figure 4.1 B, Figure 4.2). The exception in this structural class was again 
nalfurafine, which had comparable activity to the reference agonist U69,593. The arylacetamide 
compounds, which are structurally similar to the reference agonist (Figure 3.1), had comparable 
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activity as well. The exception in this structural class was the compound GR89,696, which had 
increased potency and maximal efficacy compared to U69,593 with the lowest EC50 tested in this 
assay of 8.7nM (Figure 4.1 C).  
The quinoxaline WMS 0611 had more activity than the structurally-similar WMS 0610 in 
this assay (Figure 4.1 D). Similarly, the diphenethylamine compounds had divergent activities 
(Figure 4.1 E). Both the quinoxaline and diphenethylamine classes of compounds had less 
activity overall than the reference agonist U69,593, and several of the diphenethylamine 
compounds were able to antagonist U69,593-induced ERK1/2 phosphorylation (Figure 4.2). 
These data were collected from in-cell western blots in 96-well plates (Figure 4.3 A), and 
while we were unable to use U2OS cells for these full dose-response curves, single-concentration 
data from regular western blots suggested that levels of ERK1/2 phosphorylation were similar 
for U2OS and HEK cells (Figure 4.3 B).  
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Figure 4.1. ERK1/2 phosphorylation by KOR ligands. Figures are arranged by structural 
class: (A) the endogenous ligand dynorphin A (1-17), the natural product salvinorin A and 
derivative mesyl salvinorin B, (B) morphinan compounds, (C) arylacetamide compounds, (D) 
quinoxaline compounds and (E) diphenethylamine compounds. All dose-response curves were 
normalized to the maximal U69,593 response from a concurrent sample of 10µM U69,593. 
Average EC50 and Emax values are represented as averages of 4 replicates per experiment (±SD). 
LogRAi values were estimated from these average EC50 and Emax values. For compounds with 
low intrinsic activity data from the antagonist curves were fit to the operational model of partial 
agonism to calculate LogRAi values (*). Dose-response curves are shown with a representative 
U69,593 dose-response curve, in black on each graph. U69,593 stimulation was between 160 and 
250% above normalized baseline, and all cells were incubated with compound for 20 minutes. 
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Figure 4.2. Blockade of U69,593-induced ERK1/2 phosphorylation by KOR ligands 
Compounds with low Emax values were tested as antagonists to block ERK1/2 phosphorylation by 
300nM U69,593. Maximum inhibition values were calculated as the percentage of 300nM 
U69,593 response. IC50 and Max inhibition values are represented as averages of 4 replicates 
per experiment (±SD).  
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Figure 4.3. ERK1/2 phosphorylation in different cell lines and representative in-cell 
western.  (A) A representative in-cell western blot in HEK293 cells, shown here in black and 
white. (B) Either HEK293 or DiscoverX U2OS cells were treated with 20µM ligand and levels 
of phosphorylated ERK1/2 were normalized to GAPDH expression and expressed as a percent of 
concurrent 10µM U69,593 activation. U69,593 stimulation was 160-250% of normalized 
baseline. U2OS data is from in-cell western blots with n = 4 replicates per experiment, and 
HEK293 data is from western blots with n=3 replicates per compound per experiment.   
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4.1.2 Quantifying the relationship between ERK1/2 activation and other signaling 
pathways with intrinsic relative activity metric 
 
In order to quantify each compound’s activity relative to the reference agonist U69,593 in 
this assay, we calculated the LogRAiERK value, as described in Section 1.1.2. These LogRAiERK 
values were then compared to the LogRAiG value and LogRAiArr values for each compound, 
giving measurements of “bias” between these pathways: DLogRAiG-ERK = LogRAiG  - 
LogRAiERK  (Figure 4.4) and DLogRAiArr-ERK = LogRAiArr  - LogRAiERK (Figure 4.5).  
Overall, the ΔLogRAiG-ERK were positive, indicating more G-protein signaling than 
ERK1/2 signaling compared to the reference agonist U69,593. Exceptions to this were the 
salvinorin-based compounds, as well as nalfurafine, U50,488 and several diphenethylamine 
compounds that had ΔLogRAiG-ERK values close to 0 (Figure 4.4). 
 ΔLogRAiArr-ERK values, on the other hand, were mixed. Some compounds, such as the 
endogenous peptide agonist dynorphin A(1-17) had more arrestin signaling than ERK signaling 
compared to the reference agonist, indicated by its positive ΔLogRAiArr-ERK value (Figure 4.5). 
Other compounds, like the majority of the morphinans, had negative ΔLogRAiArr-ERK  values, 
indicating more ERK signaling than arrestin signaling compared to the reference agonist in this 
system (Figure 4.5).  
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Figure 4.4. DLogRAi measurements between G-protein binding and ERK1/2 
phosphorylation for KOR ligands  
The DLogRAiG-ERK (LogRAiG – LogRAiERK) values were calculated to quantify discrepancies 
between G-protein activation and ERK phosphorylation for each compound compared to the 
reference agonist U69,593. Positive DLogRAi values indicate more G-protein signaling 
proportional to ERK1/2 phosphorylation, while negative DLogRAiG-ERK  values indicate more 
ERK1/2 phosphorylation compared to G-protein signaling, relative to the reference agonist 
U69,593. DLogRAi values are represented as the average of N=3 experiments, ±SD. DLogRAiG-
ERK values were calculated using the average EC50 and Emax as described in the methods from 
three separate experiments, and are shown here plus/minus combined standard deviations. 
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Figure 4.5. DLogRAi measurements between b-arrestin-2 and ERK1/2 phosphorylation for 
KOR ligands  
The DLogRAiArr-ERK (LogRAiArr – LogRAiERK) values were calculated to quantify discrepancies 
between b-arrestin-2 recruitment and ERK phosphorylation for each compound compared to the 
reference agonist U69,593. Positive DLogRAi values indicate more b-arrestin-2 signaling 
proportional to ERK1/2 phosphorylation, while negative DLogRAiArr-ERK values indicate more 
ERK1/2 phosphorylation compared to b-arrestin-2 signaling, relative to the reference agonist 
U69,593. DLogRAi values are represented as the average of N=3 experiments, ±SD. DLogRAiArr-
ERK values were calculated using the average EC50 and Emax as described in the methods from 
three separate experiments, and are shown here plus/minus combined standard deviations. 
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4.1.3 mTOR signaling pathway differentially regulated by KOR agonists 
We also investigated the ability of these KOR agonists to activate the mTOR signaling 
pathway at a single high concentration (10-20 µM) by western blotting for phosphorylation of the 
selective downstream target Rps6 (ribosomal protein S6, Ser240/244) in DiscoverX U2OS cells 
(Figure 4.6). All data is shown as the mean intensity of Rps6 staining, normalized to GAPDH and 
compared to the reference agonist U69,593, with 3 replicates per experiment. A representative 
western blot is shown in Figure 4.6 as well. The reference agonist U69,593 showed robust 
phosphorylation of Rps6, similar to the serum positive control for mTOR activation. KOR-
selectivity was tested by blocking Rps6 phosphorylation with norBNI co-treatment, and mTOR-
selectivity was tested by inhibiting Rps6 phosphorylation with Torin1. LY2444296 and norBNI, 
both antagonists at the KOR, were used as negative controls and showed very low levels of Rps6 
phosphorylation on their own (Figure 4.6). Almost all agonists tested showed at least 50% of 
maximum U69,593 Rps6 phosphorylation. Even lower-efficacy agonists in other assays, such as 
the morphinans naltrexone and buprenorphine, showed robust Rps6 phosphorylation in these 
western blots (Figure 4.6). 
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Figure 4.6. Rps6 phosphorylation by KOR ligands  
Rps6 phosphorylation (Ser240/244) was quantified at a high concentration (10-20uM) of each 
compound (A) and normalized to the maximum Rps6 phosphorylation by U69,593. All signal 
was normalized to GAPDH expression. Data are presented as averages of 3 replicates per 
experiment, with standard deviation error bars. U69,593 stimulation was between 100-200% of 
normalized baseline. (B) Representative western blot, with 3 replicates per condition, probed for 
GAPDH (37 kD) and phosphorylated Rps6 (ribosomal protein S6, Ser240/244 – 32 kD). 
 
4.1.4 Discussion 
 
Here, we have systematically tested a diverse set of ligands for their ERK1/2 and mTOR 
activation and compared their activity in these pathways to their activity in the early GPCR 
signaling pathways (G-protein and b-arrestin). The differential activation of all of these signaling 
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pathways is known to be dependent on what components are available in the cell, and therefore 
cell line or tissue tested. While the G-protein, b-arrestin and mTOR assays were all done in the 
DiscoverX U2OS cell lines (expressing human KOR) for comparison, these cells did not adhere 
to the plates used for the ERK1/2 phosphorylation assay. Instead, HEK cells, expressing a 
FLAG-tagged mouse KOR were used for this assay, and therefore these studies are limited by 
the fact that these assays were done in different  cell lines that express KORs of different species. 
Both HEK and U2OS cell lines showed a single peak of ERK1/2  phosphorylation in the first 20 
minutes of treatment, however, and this early-phase peak phosphorylation was used for all 
studies. Phosphorylated ERK1/2 was comparable for compounds that were tested at single 
concentrations in both cell lines (Figure 4.3).  
 Dynorphin A (1-17) showed significantly less ERK1/2 phosphorylation compared to the 
reference agonist U69,593 (Figure 4.1 A). In addition to its G-protein over arrestin bias, this 
suggests that dynorphin A(1-17) may activate the KOR differently than many of the synthetic 
agonists tested. A recent study has shown that there can be dramatic differences in the 
physiological response of the MOR between peptide and synthetic agonists,63 and our data 
suggest that the peptide dynorphin A(1-17) might also lead to differential signaling outcomes 
compared to synthetic KOR agonists. This is an important consideration for therapeutic 
development, which may rely on data from endogenous activation to establish the desired 
therapeutic effect. Salvinorin A and mesyl salvinorin B, on the other hand, showed uniquely 
robust ERK1/2 phosphorylation (Figure 4.1 A), that could potentially contribute to their unique 
downstream behavioral profiles.95 
When the activity of these compounds in the ERK1/2 phosphorylation assay was 
compared to their activity in the G-protein and b-arrestin-2 assays, the many non-zero 
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ΔLogRAiG-ERK and ΔLogRAiArr-ERK  values overall (Figure 4.4 and Figure 4.5) indicated that 
ERK1/2 phosphorylation is not directly or uniquely downstream of just one of these other 
pathways. Overall positive ΔLogRAiG-ERK values (Figure 4.4) indicated again that U69,593 may 
uniquely activate ERK1/2 phosphorylation compared to G-protein activation, and demonstrated 
further that our system is very sensitive to G-protein activation by other compounds. The smaller 
ΔLogRAiG-ERK values for salvinorin A and mesyl sal B (Figure 4.4) indicated that G-protein 
signaling may be related to ERK1/2 phosphorylation for this structural class of compounds at 
this timepoint, consistent with previous work demonstrating that early-phase ERK1/2 
phosphorylation by the KOR is G-protein mediated.96 This is also consistent with a study 
showing that both ERK1/2 phosphorylation and  Gαi activation are necessary for salvinorin A 
and mesyl salvinorin B action on dopamine transporter activity.79 However, it is clear that other 
factors contribute to ERK1/2 phosphorylation downstream of the KOR as this is not consistent 
across structural classes. 
The original study of triazole compounds demonstrated that agonist structure can impact 
ERK1/2 phosphorylation downstream of the KOR independently from G-protein / arrestin bias.62 
Additionally, studies have shown that many of the downstream signaling dynamics of both G-
protein and arrestin pathways are complex and interacting.97 These data support the idea that one 
or both early signaling pathways likely contribute to KOR-induced ERK1/2 phosphorylation, and 
that ERK1/2 phosphorylation could be mediated differently across structurally diverse agonists at 
this timepoint. It is not ideal to compare between cell lines because many signaling events are 
context-dependent, however, and future studies of many agonists in a single cellular context are 
needed.  These data support that ERK1/2 phosphorylation should be considered independently in 
studies of KOR signaling. 
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Unlike ERK1/2 phosphorylation, mTOR pathway activation has only recently been 
implicated in KOR signaling. Recent studies have demonstrated that the mTOR signaling 
pathway may be involved in mediating aversion caused by KOR agonists.36,39 These studies 
characterized several KOR agonists, including U50,488 and MCBPHA (HS665 in Liu, et al. 
2018), as activators of the mTOR pathway in the mouse striatum and cortex. They found that 
other KOR agonists, such as HS666 and nalfurafine, did not activate the mTOR pathway in these 
regions at the doses tested. They also found that mTOR activation tracked with KOR-mediated 
aversion caused by these compounds – U50,488 and MCBPHA caused aversion at the doses that 
also caused mTOR activation, while nalfurafine and HS666 were not aversive and did not cause 
mTOR activation at the doses tested. Further, they found that blocking mTOR activation was 
able to block U50,488-mediated conditioned-place aversion.  
In our experiments, robust Rps6 phosphorylation (at least 50% of maximum U69,593 
stimulation) was caused by the vast majority of agonists tested (Figure 4.6). Compounds such as 
nalfurafine, which did not show mTOR activation in previous studies at lower concentrations, 
were still robust activators of the pathway in this experiment. The differences between this study, 
in which all KOR agonists tested activated the mTOR pathway, and the previous study in which 
only a subset of KOR agonists activated the pathway, are likely due in part to differences in both 
tissue tested and concentrations used. 
Similarly to ERK1/2 phosphorylation, there are discrepancies between the early signaling 
pathways (G-protein and arrestin) and Rps6 phosphorylation in this system. Agonists that had 
very little β-arrestin-2 recruitment, such as nalmefene and naltrexone (Figure 3.2 B), still showed 
robust Rps6 phosphorylation (Figure 4.6), suggesting that G-protein activation may be more 
involved than arrestin signaling in activating the mTOR pathway. The dynamics appear more 
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complex than this, however, as agonists such as 3G1 and 3G2 showed 100% maximum effect for 
G-protein signaling but only partial Rps6 phosphorylation (Figure 3.4 E and Figure 4.6). Full 
quantitative dose-response and functional studies are needed to further elucidate the relationships 
between the early signaling pathways and complex downstream mTOR activation. Overall, these 
data demonstrate that diverse KOR agonists can differentially regulate both ERK1/2 
phosphorylation and mTOR activation (through Rps6 phosphorylation). This indicates that 
individual signaling modalities should be studied independently, and these complex downstream 
pathways should not be used as proxies for initial signaling events, as has been done in some 
studies of G-protein and arrestin bias.35 These downstream signaling pathways are likely the 
consequence of complex crosstalk between pathways, including G-protein, b-arrestin-2, and 
potentially additional signaling pathways. 
 
4.2  Identification of novel KOR-signaling pathways 
Data from other studies, as well as our ERK1/2 and mTOR studies in Chapter 2.1, have 
indicated that there are signaling pathways that can be differentially regulated by agonists at the 
KOR in addition to the well-characterized G-protein and arrestin pathways.36,62 While it is 
possible that these pathways are affected by events further downstream of the receptor, it is also 
possible that there are additional receptor-proximal signaling partners that are differentially 
regulated directly by changes in receptor conformation caused by specific agonists (Figure 4.7). 
In this case, these other signaling partners could be involved in KOR-mediated behaviors and 
used to further refine a desired ligand “bias” profile for therapeutically-beneficial downstream 
effects.  
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Here, we aimed to identify novel protein binding partners of the KOR. First, we optimized 
an immunoprecipitation protocol for a FLAG-tagged KOR. Then, we compared protein-binding 
partners of the KOR under different signaling conditions to identify differentially-regulated 
proteins.  
 
Figure 4.7. Effect of biased agonists on receptor-protein interactions 
   
4.2.1 Validation of KOR  immunoprecipitation  
First, KOR-FLAG proteins and interacting protein binding partners were 
immunoprecipitated from HEK cells to optimize the immunoprecipitation protocol using M2-
agarose beads. The sample eluted from the beads was prepared via trypsin digestion and proteins 
were identified using LC-MS/MS and FLAG-KOR proteins were additionally identified by 
western blot. We found that KOR-FLAG proteins were enriched in the immunoprecipitated 
sample relative to total protein, shown both through western blotting (Figure 4.8) and later LC-
MS/MS analysis. While only 2 KOR peptides were reliably identified in the immunoprecipitated 
samples, this is consistent with previous reports of KOR immunoprecipitations, likely due to 
poor solubility and interference from membrane components. Overall, these data indicate that the 
KOR was successfully immunoprecipitated. 
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To identify which proteins were interacting with the KOR, protein hits from the LC-MS/MS 
were analyzed by MaxQuant software and subsequently filtered, as described below. Over 1000 
proteins were identified in the experiment. First, these were filtered for their posterior error 
probability (PEP) score, which is the probability that the identification of any given peptide is 
incorrect.73 All proteins with peptide PEP scores of greater than 10-4 were eliminated, as well as 
proteins that only had 1 identified peptide. In the optimized immunoprecipitation, this left 947 
identified proteins. A significant number of these proteins were related to protein trafficking, 
including ER and Golgi-bound proteins. This indicated that much of the KOR-FLAG may not 
have been at the membrane surface, and that the proteins identified may have been unrelated to 
KOR signaling at the membrane. This is not unusual for membrane-bound proteins. However, a 
large number of signaling and receptor-related proteins were also identified (Table 4.1). Proteins 
that were expected to interact with the KOR, such as G-proteins and ubiquitin-related proteins, 
were identified, as well as proteins that have previously been shown to interact with other opioid 
receptors in previous yeast-2-hybrid experiments.98   
 
Figure 4.8. FLAG-KOR proteins enriched in 
immunoprecipitation 
FLAG-KOR proteins were immunoprecipitated and 
run on SDS-PAGE gel from both two different cell 
lysates (H and L). Lysate and eluted samples were 
stained for total protein using REVERT total protein 
stain and (grey) and FLAG (green) expression, 
showing enrichment of the FLAG-KOR protein in 
the eluted fraction.  
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Table 4.1. Signaling and receptor-related proteins identified in co-immunoprecipitation 
with FLAG-KOR. Proteins that co-immunoprecipitated with FLAG-KOR were identified by 
LC-MS/MS and data analyzed using MaxQuant software. Proteins with previously demonstrated 
interactions with opioid receptors were based on previous experiments reviewed in Georgoussi 
et. al. 2012.98 
 
 
4.2.2 SILAC preparation of cells for investigation of activation-specific interactions 
After optimizing the immunoprecipitation protocol, we used a SILAC (stable isotope-
labeled amino acids in cell culture) approach to compare protein-binding partners under different 
signaling conditions (Figure 4.9). Cells were grown with heavy (15N lysine and arginine) amino 
acid media and treated with vehicle, alongside cells grown with regular (light) amino acid media 
that were treated with 10-20µM of a KOR agonist. Cells were then lysed, membranes isolated 
and solubilized and equal amounts of protein lysate from the vehicle (heavy) and agonist-treated 
(light) samples were mixed for immunoprecipitations. Protein-receptor interactions were then 
Protein Identity LogPEP Total peptides
OPRK1, opioid receptor, kappa 1 -12.7 4
G-proteins (shown to be involved in KOR signaling)
GNAI3, guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 -52.4 8
GNAI2, G protein subunit alpha i2 -42.7 2
GNB1, guanine nucleotide binding protein (G protein), beta polypeptide 1 -77.5 12
GNB2, guanine nucleotide binding protein (G protein), beta polypeptide 2 -65.3 3
GNB2L1, guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 -22.7 5
MAPK-related proteins (shown to be involved in KOR signaling)
TAB1, TGF-beta activated kinase 1/MAP3K7 binding protein 1 -275.7 61
MAP3K7, mitogen-activated protein kinase kinase kinase 7 -195.8 39
TAB3, TGF-beta activated kinase 1/MAP3K7 binding protein 3 -63.3 9
Ubiquitin-related (shown to interact with KOR) 
UBAP2L, ubiquitin associated protein 2 like -163.9 23
RNF20, ring finger protein 20, E3 ubiquitin protein ligase -15 2
USP10, ubiquitin specific peptidase 10 -9.1 2
Ribophorin1 (shown to interact with KOR) and Ribophorin2 
RPN1, ribophorin I -205.5 34
RPN2, ribophorin II -67.5 12
Calmodulin (shown to interact with MOR and DOR)
CALM2, calmodulin 2 -99 20
Calnexin (shown to interact with DOR)
CANX, calnexin -92.4 5
Filamin A (shown to interact with MOR) and Filamin B
FLNA, filamin A -2077.7 459
FLNB, filamin B -1201.8 148
Synaptophysin (shown to interact with MOR)
SYPL1, synaptophysin-like 1 -14.1 2
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identified using LC-MS/MS, and filtered for quality by PEP score and number of peptide. 
Additionally, protein identities were matched against a database of commonly-identified proteins 
in similar protocols, to eliminate proteins that are incredibly abundant in the cell and likely to 
immunoprecipitate with many different bait proteins.99  
 
 
 
Figure 4.9. SILAC approach for identifying differences in receptor-protein interactions 
with KOR agonist treatment 
 
 
For each protein, an intensity ratio was calculated, comparing the amount of that protein in 
the light sample (treated with agonist) to the amount of that protein in the heavy sample (treated 
with vehicle). An intensity ratio of 0.5 indicated no change in intensity between the vehicle and 
treated cells. An intensity ratio of >0.5 indicated increased intensity of that protein in the agonist-
treated cells, and an intensity ratio of <0.5 indicates decreased intensity of that protein in the 
agonist-treated cells. The range of intensity ratios was not very large for the proteins identified 
(0.6-0.4), suggesting that there were not large fluctuations in receptor-protein interactions with 
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agonist treatment overall. The intensity ratios were consistent across two replicates, however 
(Figure 4.10), suggesting that these small fluctuations in intensity ratio may be biologically 
relevant. 
 
 
 
Figure 4.10. Intensity ratios consistent across SILAC replicates 
Intensity ratios were calculated as the [Intensity in Light Sample / (Intensity in Light Sample + 
Intensity in Heavy Sample)]. An intensity ratio of 0.5 indicates equal intensity in both the 
vehicle-treated (Heavy) and KOR agonist-treated (Light) sample. Replicate data are shown for 
10 proteins that were reliably identified across several different experiments, with filtering as 
described in the text and methods. In this case, both replicates compared 10µM U69,593 and 
vehicle treatments.  
 
4.2.3 Ligand identity affects activation-specific interactions  
Intensity ratios for many proteins were then compared for different agonist treatments 
including the reference agonist U69,593, the G-protein biased diphenethylamine agonist 
MCBPHA or the extremely G-protein biased diphenethylamine agonist BPHA (Figure 4.11). In 
each graph, a dot represents a single protein that was identified in all experiments. The intensity 
ratios from the different agonist treatments for each protein were then plotted against each other. 
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Intensity ratios for the proteins in the sample treated with U69,593 did not correlate with the 
intensity ratios for the same proteins in samples treated with either MCBPHA or BPHA (Figure 
4.11 A, B). Intensity ratios for proteins in the sample treated with MCBPHA did show a 
significant correlation with the intensity ratios for the same proteins in the sample treated with 
BPHA (Figure 4.11 C).  
 
 
Figure 4.11. Intensity ratios for proteins identified in co-immunoprecipitations after 
different treatment conditions 
Intensity ratios were calculated for protein-receptor interactions when vehicle-treated cell were 
compared with U69,593-treated cells, BPHA-treated cells and MCBPHA-treated cells and 
intensity ratios compared here. Each dot represents an individual protein that interacted with the 
KOR under all conditions tested. There was no significant correlation between the U69,593-
treated intensity ratios and either (A) MCBPHA or (B) BPHA-treated intensity ratios. (C) There 
was a significant correlation (Pearson r = 0.41, p<0.001)  between the MCBPHA and BPHA-
treated intensity ratios.  
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Table 4.2 shows the intensity ratios for 10 of the top proteins in all 3 treatment conditions. 
Four of the proteins are involved in protein folding and trafficking, suggesting that many of the 
candidate proteins identified may be background noise. Interestingly, 2 of these top 10 proteins 
are involved in 14-3-3 signaling (TRIM25 and STRAP).  
 
 
 
 
Table 4.2. Intensity ratios for top 10 proteins identified in all co-immunoprecipitations 
Descriptions of the top 10 protein-receptor interactions in all treatment conditions (based on 
filtering criteria described in text and methods) and intensity ratios for different treatment 
conditions. Proteins marked with an asterisk(*) were involved in membrane-protein trafficking 
and processing.  
 
 
4.2.4 14-3-3 localization affected by KOR activation 
14-3-3 proteins are ubiquitously expressed signaling scaffolds, that have been shown to play 
an important role in GPCR signaling, and to interact with the KOR under different 
conditions.100,101 To assess the effect of KOR activation on 14-3-3 signaling, we looked at 14-3-3 
localization in HEK cells expressing a GFP-tagged KOR following treatment with U69,593 
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(Figure 4.12). When cells were treated with vehicle, in this case serum-free DMEM media, 14-3-
3 was localized to the cytoplasm of the cell. After 1 hour treatment with 10uM of the full, 
unbiased KOR agonist U69,593, however, a portion of the 14-3-3 protein was localized to the 
nucleus of the cell (Figure 4.12 B).  
To investigate this further, high-throughput imaging of 200-300 nuclei per sample indicated 
a dose-dependent increase in 14-3-3 nuclear localization with increasing concentrations of 
U69,593 (Figure 4.13). This effect was partially blocked by co-treatment of the cells with the 
KOR-selective antagonist norBNI, suggesting that this effect is mediated by KOR (Figure 4.13).  
While one-way ANOVA revealed a significant effect of treatment (F(4,2098) = 28.47), the 
overall effect size was small, with only 5% of the variation coming from different treatment 
conditions (h2 = 0.05).  
 
Figure 4.12. 14-3-3 proteins localize to the nucleus after KOR activation  
HEK cells expressing a GFP-tagged KOR were stained for pan-14-3-3 expression (grey) and 
imaged with confocal microscopy. Cells were treated with (A) vehicle and (B) 10µM U69,593.  
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Figure 4.13. U69,593 treatment causes dose-
dependent nuclear localization of 14-3-3 
HEK cells expressing GFP-tagged KOR were plated in 
96-well plates, treated with varying doses of the agonist 
U69,593 and stained with DAPI and for pan-14-3-3 
localization using wide-field microscopy. Intensity of 
14-3-3 staining in the nucleus was quantified by co-
localization with DAPI staining. Data are represented as 
the mean of 600-1200 nuclei from two samples (±SD).  
 
 
 
 
4.2.5 Discussion 
The identification of additional pathways directly involved in GPCR signaling has been 
historically difficult, due to the technical complexity of biochemical experiments with 
membrane-bound proteins. Previously, work has been done to identify phosphorylated proteins 
that were differentially regulated by structurally diverse GPCR agonists (including the 
KOR),36,102 and as well as to identify proteins that differentially interact with arrestins after 
agonist activation.103 More recently, innovative methods for labeling proteins in close proximity 
to opioid receptors after agonist activation have identified potential novel protein-receptor 
interactions as well.104 Here, we attempted to directly identify novel protein-receptor interactions 
through immunoprecipitation and mass spectrometry, using an isotope-labeling approach (Figure 
4.9).  
 First, we validated our immunoprecipitation by comparing the proteins that we identified 
in our sample to a list of proteins that had previously been identified as interactors with opioid 
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receptors (Table 4.1). Combined with the clear enrichment of FLAG-KOR protein in our eluted 
sample (Figure 4.8), these data suggested that our immunoprecipitation likely included proteins 
that interacted with the KOR at the membrane where it could be activated by agonists. To 
identify proteins specifically involved in signaling, we compared protein-receptor interactions 
when the cells were treated with vehicle to interactions when the cells were treated with a KOR 
agonist using stable-isotopes to label amino acids in the different cell populations (Figure 4.9).  
 With the intensity ratios calculated from these samples, we examined both the larger 
patterns of receptor-protein interaction as well as specific candidate proteins. When comparing 
the intensity ratios of all of the proteins identified, we found that the structurally similar 
diphenethylamine agonists had correlated intensity ratios, while U69,593 did not (Figure 4.11). 
This suggests that the intensity ratios for proteins, which is a measure of the change in binding 
interaction upon KOR activation, was related to the ligand identity, and many proteins could be 
differentially regulated by agonist identity. Additional studies with diverse agonists could help to 
identify relationships between intensity ratios overall and any specific feature of agonists - such 
as G-protein or arrestin signaling, a certain structural feature, or even a downstream behavior.  
 We then examined specific proteins that interacted with the KOR for candidate signaling 
pathways that may be involved in KOR signaling. Of the 10 most abundant proteins that were  
identified in all samples (after filtering as described in the methods), two were involved in 14-3-3 
signaling (Table 4.2). We found a weak, but significant, dose-dependent increase in 14-3-3 
nuclear localization following treatment of cells with U69,593, and this was partially blocked by 
the KOR-selective antagonist norBNI (Figure 4.12, Figure 4.13). These experiments used a pan-
14-3-3 antibody, however, so further investigation into the subtypes of 14-3-3 involved in KOR 
signaling are necessary. 14-3-3 proteins are ubiquitously and abundantly expressed, actually 
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comprising 1% of all protein in the brain.105 For this reason, 14-3-3 proteins themselves often 
emerge as hits in high-throughput protein expression screens like the one here. Despite this, the 
imaging data, along with previous data describing 14-3-3 and KOR interactions, suggests that 
14-3-3 may be involved in KOR signaling in a meaningful way that involves nuclear 
localization.  
 It has been shown recently that 14-3-3 signaling can be differentially regulated 
downstream of GPCRs, depending on agonist identity.100 Further investigation into the 
regulation of 14-3-3 by diverse KOR agonists, particularly agonists that are known to be biased 
for other pathways, will be important for elucidating the role that 14-3-3 proteins play in 
regulating the signaling or trafficking of the KOR. Additionally, the majority of GPCR-14-3-3 
research has focused on the role of 14-3-3 as a scaffolding protein. Further research into the role 
of 14-3-3 in the nucleus following GPCR activation is needed.  
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CHAPTER 5. IN VIVO EFFECTS OF DIFFERENT KOR AGONISTS 
 
5.1 Effect of diverse KOR agonists on prolactin release in mice 
In addition to mediating the effects of drugs of abuse, the dopaminergic effects 
downstream of opioid receptors regulate other processes in the brain and body. For example, the 
release of the hormone prolactin is under inhibitory control by dopamine, from neurons 
projecting from the hypothalamus to the pituitary. Prolactin is known for its involvement in 
pregnancy and lactation, however it also plays an important part in the stress response.106 It has 
been shown that activation of the KOR by dynorphin peptides following stress,107,108 or by 
exogenous KOR agonists, 109,110 leads to an increase in prolactin levels, mediated by dopamine in 
this tuberoinfundibular dopaminergic system.  
Work from Butelman, et. al. has shown that levels of prolactin can be used as a 
quantitative biomarker of KOR activation,111 and prolactin levels have been used in rodents,86 
non-human primates112 and humans32 to investigate KOR activity in vivo. In this study, we 
investigated the effects of several, structurally diverse KOR agonists on the release of prolactin 
in mice. 
 
5.1.1 Prolactin release caused by diverse KOR agonists 
 For all experiments, mice were injected intraperitoneally with compound or vehicle and 
then sacrificed 30 minutes later (unless otherwise noted) and trunk blood was collected. Prolactin 
levels in the serum were measured by sandwich ELISA. We found an increase in serum prolactin 
after treatment with the full, unbiased arylacetamide agonist U50,488, and that this increase was 
blocked, at least in part, by a KOR-selective dose of the antagonist LY2444296 (Figure 5.1). The 
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diphenethylamine compounds BPHA, MCBPHA and MCPPHA all caused significant prolactin 
release at doses of 30mg/kg (Figure 5.1), and these effects were blocked by the antagonist 
LY2444296. 
 We also examined the morphinan compound nalfurafine, that had a unique signaling 
profile in vitro (Figure 3.2, Figure 3.3). A dose of 10µg/kg nalfurafine caused significant 
prolactin release after 30 minutes compared to saline treatment (Figure 5.2 A). This effect was 
blocked by the KOR-selective dose of LY2444296, indicating that this nalfurafine-induced 
prolactin release was mediated by the KOR (Figure 5.2 A). The lower dose of 3µg/kg nalfurafine 
caused significant prolactin release, however there was no effect of the doses lower than this (1 
and 0.3µg/kg nalfurafine) (Figure 5.2 B). Levels of prolactin in the serum remained elevated for 
at least 60 minutes after intraperitoneal injection of 10µg/kg nalfurafine, but returned to normal 
by 120 minutes (Figure 5.2 C).  
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Figure 5.1. Prolactin release caused by U50,488, and diphenethylamine compounds. Mice 
were pretreated with either vehicle or 3mg/kg LY2444296 15 minutes before an injection of 
30mg/kg U50,488, MCBPHA, BPHA or MCPPHA. Serum prolactin levels were measured in 
samples taken 30 minutes after the second injection. * = p < 0.05, *** = p < 0.0005, **** = p < 
0.0001, by one-way ANOVA followed by followed by Dunnett’s multiple comparison test 
compared vehicle-saline control group. Each experiment was tested independently for 
significance.  
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Figure 5.2. Prolactin release caused by the morphinan compound nalfurafine. A. Mice 
received an injection intraperitoneally of either LY2444296 or vehicle 15 minutes before an 
injection of 10µg/kg nalfurafine. Samples were collected 30 minutes after the second injection. 
Two-way ANOVA (LY244296 pretreatment x Nalfurafine treatment) revealed a significant 
effect of both LY2444296 pretreatment (F(1,30) = 86.75, p < 0.0001), Nalfurafine treatment 
(F(1,30) = 115.3, p < 0.0001) and their interaction (F(1,30) = 96.36, p < 0.0001). Newman-Keuls 
multiple comparison test revealed significant differences between Vehicle/Nalfurafine group and 
all other groups (****p<0.0001). B. Serum prolactin levels were measured in samples taken 30 
minutes after intraperitoneal injection of varying doses of nalfurafine. One-way ANOVA 
revealed a significant effect of Treatment (F(4,35) = 9.67, p < 0.0001). Dunnett’s multiple 
comparison test revealed significant differences between nalfurafine or U50,488 treated groups 
and saline-treated control group (*p < 0.05, ***p < 0.0005). C. Serum prolactin levels were 
measured in samples taken 15-120 minutes after intraperitoneal injection of 10µg/kg nalfurafine 
or saline. Two-way ANOVA (Treatment x Time) revealed a significant effect of Treatment 
(F(1,56) = 62.56, p < 0.0001), Time (F(3,56) = 7.24, p < 0.0005) and their interaction (F(3,56) = 
5.73, p < 0.005). Newman-Keul’s multiple comparison at each timepoint revealed significant 
differences between saline and nalfurafine-treated groups (**p < 0.005, ***p < 0.0005, ****p < 
0.0001).  
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5.1.2 Discussion 
 All compounds tested were compared to a concurrently-run vehicle or saline-treated 
group, in order to control for the variation in prolactin levels caused by handling and stress 
across animal groups. All of the compounds tested caused an increase in serum prolactin, 
including the extremely G-protein biased agonist BPHA (Figure 5.1). This increase in prolactin 
was blocked by the KOR-selective dose of the antagonist LY2444296 (Figure 5.1). BPHA 
showed no measurable arrestin recruitment in the PathHunter DiscoverX assay, and was able to 
block arrestin recruitment caused by the full agonist U69,593 (Figure 3.2 E, Figure 3.3 B). This 
suggests that arrestin recruitment is not required for prolactin release, and potentially not 
required for the effects of KOR activation on dopamine levels, at least in the tuberoinfundibular 
dopamine system. Additional research into the mechanism of KOR modulation of dopamine tone 
in different dopaminergic systems will be important for understanding more about prolactin 
release as a biomarker for KOR activation, as well as for understanding more about KOR actions 
on dopamine levels in general.  
   
 
5.2 Effects of KOR agonists on sedative and aversive side effects in mice 
KOR agonists have also been shown to cause side effects such as sedation and aversion 
in human and animal models that have stalled the development of KOR agonists as therapeutics. 
To avoid these negative side effects, there has been a focus on the development of biased 
agonists at the KOR, particularly with more G-protein than arrestin activity.50 Several studies of 
G-protein biased agonists, along with the work that is presented in Chapter 3, suggest that 
arrestin recruitment is required for KOR-mediated sedation.34,51,52  It is unclear, however, if this 
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signaling pathway is related to the aversive or dysphoric side effects of KOR agonists. Several of 
the studies of G-protein biased agonists have shown that they cause antinociception or 
antipruritus without causing dysphoria or anhedonia,51,52 and mechanistic studies have shown 
that arrestin-dependent p38 phosphorylation is needed for this KOR-mediated aversion.59 
However, recent studies have also suggested that the mTOR pathway is necessary for KOR-
mediated aversion, but not sedation, suggesting that these negative side effects could be 
mediated by different signaling pathways.36,39 Here, we examined the effect of BPHA, an 
extremely G-protein biased agonist with no measurable arrestin recruitment on conditioned-place 
aversion. 
Data from previous human studies are also essential for establishing the translational 
potential of KOR agonists. Interestingly, there is only one selective KOR agonist that is currently 
in clinical use in humans. Nalfurafine was approved to treat pruritus in Japan in 2009, and post-
marketing studies of over 3,000 patients have shown very few KOR-associated side effects.37 In 
rodent studies, nalfurafine has been shown to cause antipruritic and antinociceptive effects at 
doses that do not cause sedation or aversion, while traditional KOR agonists like U50,488 and 
salvinorin A caused both the therapeutic and side effects at similar doses.35,78,113 There are fewer 
studies, however, comparing the effective doses of KOR agonists in modulating drug-related 
behaviors compared to negative side effects. Here, we also examined the effects varying doses of 
nalfurafine on KOR-mediated sedation to compare to other in vivo effects such as prolactin 
release (Subsection 5.1) and the modulation of cocaine-induced behaviors (Subsection 5.3). 
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5.2.1 Sedation caused by KOR agonists measured by rotarod assay 
Multiple doses of the arylacetamide compound U50488 and the morphinan compound 
nalfurafine were tested for rotarod sedation. As noted in Chapter 3.2, high doses of both of these 
compounds caused very robust sedation in the rotarod assay at 30 minutes post-injection (Figure 
3.8). This maximally effective dose of 30mg/kg U50,488 was sedative almost immediately after 
injection, with rotarod performance beginning to recover at 60 minutes post-injection (Figure 
5.3). 10mg/kg U50,488 was sedative compared to a saline control group only 30 minutes post-
injection, while mice treated with 3mg/kg U50,488 were not impaired in the rotarod assay at any 
timepoint tested (Figure 5.3) 
100µg/kg nalfurafine caused significant sedation, as measured by the rotarod assay, 
compared to a saline injected group (Figure 5.4 A). This effect was completely blocked by a 
KOR-selective dose of 3mg/kg LY2444296, indicating that this nalfurafine-induced sedation was 
mediated by the KOR (Figure 5.4 A). Higher doses of 300µg/kg and 3mg/kg nalfurafine caused 
significant sedation in this assay; mice performed at approximately 13% of their baseline 
performance after 30 minutes and the effect was still significant after 60 minutes (Figure 5.4 B). 
Mice had fully recovered after 24 hours, however. A dose of 30µg/kg nalfurafine had 
comparable sedation to a moderate dose of 10mg/kg U50,488  (Figure 5.4 C). At the doses of 
3µg/kg and 10µg/kg however, there was no significant effect on rotarod sedation compared to 
saline injections at the same timepoint (Figure 5.4 C).  
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Figure 5.3 Rotarod sedation caused by U50,488. Mice were treated with varying doses of 
U50,488 or saline and rotarod performance was measured at selected timepoints after injection, 
and compared to baseline. Two-way ANOVA (Treatment x Time) revealed a significant effect of 
Treatment (F(3,24) = 13.77, p < 0.0001), Time (F(2,48) = 7.05, p , 0.005) and their interaction 
(F(6,48) = 3.03, p < 0.05). Dunnett’s multiple comparison test at each timepoint revealed 
significant differences between U50,488 and Saline treated groups (**p < 0.005, ****p < 
0.0001). 
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Figure 5.4. Rotarod sedation caused by nalfurafine. Rotarod performance was measured at 
select timepoints after IP injection of KOR nalfurafine, or saline, and compared to baseline 
rotarod performance in all experiments. A. Mice were pretreated for 15 minutes with 
3mg/kgLY2444296 before injection with 100µg/kg nalfurafine. There was no effect of 
LY2444296 alone on rotarod sedation (see Dunn and Reed, 2018).86 Two-way ANOVA 
(Treatment x Time) revealed a significant effect of Treatment (F(2,21)=14.38, p < 0.0005), Time 
(F(2,24)=7.99, p < 0.005) and their interaction (F(4,42)=2.66, p<0.05). Dunnett’s multiple 
comparison test at each timepoint revealed significant differences between the Vehicle/Saline 
control group and Vehicle/Nalfurafine group only (**p<0.005, ***p<0.0005). B. Two-way 
ANOVA (Treatment x Time) revealed a significant effect of Treatment (F(4,31) = 48.72), p < 
0.0001), Time (F(2,62) = 26.64, p < 0.0001) and their interaction (F(8,62) = 4.0, p < 0.0005). 
Dunnett’s multiple comparison test at each timepoint revealed significant differences between 
nalfurafine treatment groups and Saline-treated control group (**p < 0.05, *** = p < 0.0005, 
**** = p < 0.0001). C. Two-way ANOVA (Treatment x Time) revealed a significant effect of 
Treatment (F(4,30) = 3.38), p < 0.05) and Time (F(2,60) = 7.12, p < 0.005) but no effect of their 
interaction (F(8,60) = 1.19). Dunnett’s multiple comparison test at each timepoint revealed 
significant differences between nalfurafine and U50,488 treatment groups and Saline-treated 
control group (**p < 0.05).  
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5.2.2 Aversion caused by KOR agonists measured by place conditioning assay 
For the conditioned-place aversion assay, mice were first allowed to freely explore the 3-
chamber apparatus and the time spent in each chamber was recorded. During conditioning 
sessions, mice received an injection of vehicle or KOR agonist and were placed in the drug-
paired chamber for 30 minutes. The same day, they received an injection of vehicle or KOR 
agonist (opposite of AM injection) and were immediately placed in the opposite chamber for 30 
minutes. Chambers had different colored walls, as well as different textured floors. The day after 
all conditioning sessions were finished, mice were allowed to freely explore the 3-chamber set 
up again and the time spent in each chamber was recorded. If mice spent less time in the drug-
paired chamber after the conditioning sessions than they did before the conditioning sessions, 
that suggested aversion to the drug-paired context, and by extension, the drug. 
Several KOR agonists were tested at doses that were non-sedative. The non-sedative dose 
of 3mg/kg U50,488 did not cause any difference in time spent in the drug-paired chamber 
(Figure 5.5), suggesting that it was not aversive. Nalfurafine, at doses of both 3µg/kg and 
10µg/kg, also did not cause any change in time spent in the drug paired chamber compared to 
saline (Figure 5.6 A and B). When mice were treated with 30mg/kg of the extremely G-protein 
biased diphenethylamine agonist BPHA before conditioning, however, they spent significantly 
less time in the drug-paired chamber compared to the vehicle-paired chamber (Figure 5.7). 
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Figure 5.5. Conditioned-place aversion with a non-sedative dose of U50,488  
Mice were injected IP with 3mg/kg U50,488, and then injected with saline and placed in drug-
paired chambers 15 minutes later. Mice were conditioned for 2 session (30 minutes each) in the 
paired chamber, as well as 2 sessions (30 minutes each) in the opposite chamber following 
injections of saline in place of drug. Data is represented as the difference in the time spent in the 
paired chamber after the conditioning sessions, compared to before the conditioning sessions. 
There was no effect of treatment by unpaired T-test. 
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Figure 5.6 Conditioned-place aversion with non-sedative doses of nalfurafine 
Mice were IP injected with 3µg/kg (A) or 10µg/kg (B) nalfurafine, and then injected with saline 
and placed in drug-paired chambers 15 minutes later. Mice were conditioned for 2 session (30 
minutes each) in the paired chamber, as well as 2 sessions (30 minutes each) in the opposite 
chamber following injections of saline in place of drug. Data is represented as the difference in 
the time spent in the paired chamber after the conditioning sessions, compared to before the 
conditioning sessions. There was no effect of treatment by unpaired T-test in either experiment. 
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Figure 5.7 Conditioned-place aversion caused by BPHA   
Mice were conditioned for 4 sessions (30 minutes each) in a paired chamber following IP 
injection of either vehicle or 30mg/kg BPHA as well as 4 sessions (30 minutes each) in the 
opposite chamber following injection of vehicle. Data is represented as the difference in the time 
spent in the paired chamber after the conditioning sessions, compared to before the conditioning 
sessions. T-test revealed significant effect of BPHA treatment compared to vehicle (*p<0.05).  
 
5.2.3 Discussion 
Here, we found that although high doses of the full agonists U50,488 and nalfurafine 
were extremely sedative, lower doses were not sedative or aversive in these assays. Low doses of 
nalfurafine, such as the 3µg/kg and 10µg/kg doses tested here, have been shown to cause 
antipruritic and antinociceptive effects, as well as prolactin release (Figure 5.2), suggesting that 
they are still able to activate the KOR. Higher doses of nalfurafine, have been shown to be 
sedative, 114,115  consistent with findings here (Figure 5.4). These data are also consistent with 
previous studies demonstrating that nalfurafine is more potent for therapeutic endpoints, in this 
case prolactin release, than side effects like sedation. Here, nalfurafine at 3µg/kg and 10µg/kg 
caused significant prolactin release (Figure 5.2) but not sedation (Figure 5.4).  
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While our CPA findings are consistent with other groups demonstrating that these doses 
of nalfurafine are not aversive, a recent study found that 10µg/kg nalfurafine could potentially 
increase thresholds in intracranial self-stimulation, suggesting that it could cause dysphoria, 
depending on the assay used.116  
Interestingly, BPHA, which is an extremely G-protein biased agonist with no measurable 
arrestin activity (Figure 3.2), caused significant aversion compared to vehicle (Figure 5.3). This 
suggests that arrestin recruitment may not be necessary for the aversive side effects of KOR 
agonists, in the way that arrestin recruitment appears to be necessary for the sedative side effects 
of KOR agonists. Recent work has shown that the mTOR signaling pathway may be important 
for KOR-mediated aversion, but not sedation, and these data further support that these two 
negative side effects are mediated by different signaling pathways. Further research into the 
signaling mechanisms and circuits that lead to these behaviors is necessary to better understand 
how to develop drugs that can activate the KOR for therapeutic purposes, while avoiding 
aversive side effects. 
 
5.3 Effect of KOR agonists on cocaine-related behaviors in mice 
In addition to pain and pruritus, KOR agonists have been of particular interest in treating 
cocaine and psychostimulant addiction, as KOR activation inhibits the dopamine release caused 
by these drugs17 and there are currently no available treatments for these diseases. KOR agonists 
have been shown to block the rewarding effects of drugs of abuse, including cocaine. Because of 
its positive clinical and post-marketing data in treating pruritus, nalfurafine is of particular 
interest for future clinical studies in this area. However, there are few studies that have examined 
effects of nalfurafine on cocaine-related behavior or comparing nalfurafine and other KOR 
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agonists head-to-head for this therapeutic effect.114,117 Here, we investigated the effects both 
nalfurafine and the full KOR agonist U50,488 in two mouse models of cocaine-induced reward 
at doses that did not cause sedative side effects (Figure 5.3 and Figure 5.4).  
 
5.3.1 Effect of KOR agonists on cocaine-conditioned place preference 
In a 3-chamber conditioned place preference paradigm, similar to the CPA assay in 
Subsection 5.2.1, mice that were conditioned with an injection of 15mg/kg cocaine spent more 
time in the drug-paired chamber after conditioning, indicating cocaine preference or reward, as 
expected. When mice were pretreated for 15 minutes with a relatively low dose of 3mg/kg 
U50,488 before receiving cocaine, however, this preference was attenuated  (Figure 5.8).  When 
mice were pretreated for 15 minutes with 10µg/kg nalfurafine (Figure 5.9 A) or 3µg/kg 
nalfurafine (Figure 5.9 B), conditioned-place preference for the cocaine-paired chamber was also 
attenuated. These same doses of U50,488 and nalfurafine were not aversive on their own (Figure 
5.5 and 5.6). 
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Figure 5.8. U50,488-induced blockade of cocaine-conditioned place preference. Mice were 
treated with 3mg/kg U50,488 or saline, and then 15 minutes later treated with 15mg/kg cocaine 
or saline before immediately being placed in appropriate conditioning chambers for 30 minutes. 
4 total conditioning sessions were done, 2 in each box, across 2 days. Two-way ANOVA 
(U50,488 Pretreatment x Cocaine Treatment) revealed a significant effect of Cocaine Treatment 
(F(1,36) = 5.11, p < 0.05) but no effect of U50,488 Pretreatment (F(1,36) = 1.60) or interaction 
(F(1,36) = 4.07). Newman-Keuls multiple comparison test revealed significant differences 
Cocaine group and all other groups (*p<0.05).  
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Figure 5.9. Nalfurafine blockade of cocaine-conditioned place preference. A. Mice were 
treated with 10µg/kg nalfurafine or saline, and then 15 minutes later treated with 15mg/kg 
cocaine or saline before immediately being placed in appropriate conditioning chambers for 30 
minutes. 4 total conditioning sessions were done, 2 in each box, across 2 days. Two-way 
ANOVA (Nalfurafine Pretreatment x Cocaine Treatment) revealed significant effect of Cocaine 
Treatment (F(1,32) = 22.59, p < 0.0001) but not Nalfurafine Pretreatment (F(1,32) = 1.68), as 
well as a significant Cocaine x Nalfurafine interaction (F(1,32) = 9.01, p < 0.01). Post-hoc 
Newman-Keuls analysis revealed significant differences between Saline/Cocaine and 
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Nalfurafine/Cocaine (**p < 0.005), Nalfurafine/Saline (**p < 0.005) and Saline/Saline (***p < 
0.0005) and no differences between other groups. B. Mice were treated with 3µg/kg nalfurafine 
or saline, and then with 15mg/kg cocaine or saline using identical methods. Two-way ANOVA 
(Nalfurafine Pretreatment x Cocaine Treatment) revealed no significant effect of Cocaine 
Treatment (F(1,28) = 2.06) or Nalfurafine Pretreatment alone (F(1,28) = 1.88), however there 
was a significant Cocaine x Nalfurafine interaction (F(1,24) = 5.22, p < 0.05). Post-hoc 
Newman-Keuls analysis revealed significant difference between Saline/Cocaine and 
Nalfurafine/Cocaine (*p<0.05). 
  
5.3.2 Effect of KOR agonists on cocaine self-administration after acquisition 
Effects of these lower doses of U50,488 and nalfurafine were tested in a model of 
intravenous cocaine self-administration in mice as well. After 7 days of cocaine self-
administration, at 0.5mg/kg/infusion for 2 hours on an FR1 schedule, mice were reliably self-
administering cocaine at a mean dose of 12mg/kg over the 2 hour sessions (Figure 5.10). When 
mice were then immediately pretreated with a subcutaneous injection of 3mg/kg U50,488 or 
saline before self-administration sessions, the U50,488-treated mice increased cocaine intake 
(Figure 5.10). Similarly, a pretreatment of 10µg/kg nalfurafine caused an apparent increase in 
cocaine intake in the same paradigm. A 15 minute pretreatment with 3mg/kg of the antagonist 
LY2444296 before the nalfurafine injection blocked this effect, suggesting that it is KOR-
mediated (Figure 5.11). Although the nalfurafine-treated group was only statistically significant 
compared to the LY/Saline control group on one day, this trend persisted over 7 consecutive days 
(Figure 5.11). In the same paradigm, pretreatment with a smaller dose of 3µg/kg nalfurafine
alone had no effect on cocaine self-administration compared to saline, demonstrating a dose-
dependent profile of this KOR agonist (Figure 5.12). 
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Figure 5.10. Effect of U50,488 on cocaine IVSA in mice, after acquisition. Mice 
intravenously self-administered 0.5mg/kg/infusion cocaine under an FR1 schedule for 2 hours 
daily until acquisition was stable (<20% variation across two consecutive days) and >70% of 
total nose pokes were in the active hole. Mice were injected with 3mg/kg U50,488 or saline 
immediately before IVSA sessions on pretreatment days. A. Daily cocaine intake. Two-way 
ANOVA (Treatment x Time), with repeated measures on Time, revealed a significant effect of 
Treatment (F(1,12) = 5.84, p < 0.05) and Time (F(8,96) = 15.78, p < 0.0001) but no interaction 
(F(8,96) = 1.49). Sidak’s multiple comparison test for each day revealed a significant difference 
between Saline and U50,488-treated groups on Day 8 (*p < 0.05).  B. Average cocaine intake 
during the pretreatment days (Days 8 and 9).  
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Figure 5.11. Effect of 10µg/kg nalfurafine on cocaine IVSA in mice, after acquisition. Mice 
intravenously self-administered 0.5mg/kg/infusion cocaine under an FR1 schedule for 2 hours 
daily until acquisition was stable (<20% variation across two consecutive days) and >70% of 
total nose-pokes were in the active hole. Mice were injected with 3mg/kg LY2444296 or vehicle, 
and then 15 minutes later injected with 10µg/kg nalfurafine or saline immediately before IVSA 
sessions on pretreatment days. A. Daily cocaine intake. Two-way ANOVA (Overall treatment 
condition x Time), with repeated measures on Time, revealed no overall effect of Treatment 
(F(3,24) = 0.75), but a significant effect of both Time (F(12,288) = 7.31, p <0.0001) and 
Treatment x Time Interaction (F(36,288) = 1.63, p < 0.05). Sidak’s multiple comparisons test for 
each day revealed only a significant difference between Vehicle/Nalfurafine group and the 
LY/Saline group on Day 11 (*p<0.05).  B. Average cocaine intake during the pretreatment days. 
Two-way ANOVA (LY Pretreatment x Nalfurafine Treatment) revealed no significant effect of 
LY244296 pretreatment alone (F(1,24) = 1.67), or nalfurafine treatment alone (F(1,24) = 2.67), 
however there was a significant interaction of LY2444296 x nalfurafine (F(1,24) = 4.71, p < 
0.05). Newman-Keuls post-hoc analysis revealed a significant difference between 
Vehicle/Nalfurafine and LY/Saline groups (*p < 0.05).  
 
 112
 
 
 
 
 
 113 
 
Figure 5.12. Effect of 3µg/kg nalfurafine on cocaine IVSA in mice, after acquisition. Mice 
intravenously self-administered 0.5mg/kg/infusion cocaine under an FR1 schedule for 2 hours 
daily until acquisition was stable (<20% variation across two consecutive days) and >70% of 
total nose-pokes were in the active hole. On pretreatment days (8-14), mice were injected with 
3µg/kg nalfurafine or saline immediately before IVSA sessions. Two-way ANOVA (Treatment x 
Time), with repeated measures on Time, showed a significant effect of Time (F(13,234) = 9.17), 
but no effect of Treatment (F(1,18) = 0.194). 
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5.3.3 Effect of nalfurafine on acquisition of cocaine self-administration 
In an additional experiment, mice were treated with 10µg/kg nalfurafine during the initial 
acquisition of cocaine self-administration. These mice immediately increased their intake of 
cocaine compared to saline-treated animals (Figure 5.13). This effect appeared to be temporary 
and reversible, as the nalfurafine-treated mice returned to saline-treatment levels when they 
received saline injections instead (Figure 5.13).  
 
 
Figure 5.13. 10µg/kg nalfurafine on acquisition of cocaine IVSA in mice. Mice were given 
pretreatment injections of 10µg/kg nalfurafine or saline immediately before IVSA sessions for 
Days 1-6 and Days 9 and 10. All mice were given saline injections immediately before IVSA 
sessions on Days 7 and 8. IVSA sessions were 2 hours, on an FR1 schedule with 
0.5mg/kg/infusion cocaine. Two-way ANOVA (Treatment x Time), with repeated measures on 
Time,  revealed a significant effect of Treatment (F(1,29) = 7.64, p<0.01), Time 
(F(9,261(=11.42, p<0.0001), and interaction (F(9,261)=3.01, p<0.005). Sidak’s multiple 
comparisons test for each day revealed significant differences between Group 1 and Group 2
(*p<0.05, **p<0.005). 
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5.3.4 Discussion 
In these assays, both U50,488 and nalfurafine were able to modulate cocaine-related 
behaviors at doses that were not aversive and not sedative. The doses of 3µg/kg and 10µg/kg 
nalfurafine, for example, were not sedative in the rotarod assay (Figure 5.4 A and B) and did not 
cause aversion on their own (Figure 5.6), but were able to block cocaine-conditioned place 
preference (Figure 5.9). These doses of nalfurafine also caused significant prolactin release, 
demonstrating that nalfurafine still activated the KOR in mice at this dose (Figure 5.2 A and B). 
The dose of 3mg/kg of U50,488 was also able to block cocaine-induced CPP without causing 
aversion on its own (Figure 5.5 and Figure 5.8), suggesting that this beneficial therapeutic 
window, between modulation of cocaine-related behavior and aversion, may be a property of the 
KOR system in general and not unique to nalfurafine. This is in contrast to studies of the 
antinociceptive and antipruritic effects of nalfurafine and other KOR agonists, but consistent 
with previous CPP and self-administration studies demonstrating that anti-reward and aversive 
effects of KOR agonists can be uncoupled. The mechanism of this uncoupling could be related to 
different signaling mechanisms, as has been suggested for the uncoupling of therapeutic effects 
and sedation, however it is also possible that both anti-reward and aversion are mediated by 
dopamine inhibition downstream of the KOR and their uncoupling is a result of different 
thresholds.  
 Interestingly, both 3mg/kg U50,488 and 10µg/kg nalfurafine had opposing effects on 
cocaine-conditioned place preference and cocaine IVSA. At these doses, both compounds 
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blocked cocaine CPP, but caused significant potentiation of cocaine self-administration after 
mice had already acquired self-administration behavior (Figures 5.10 and 5.11). In the CPP 
assay, mice received a nalfurafine pre-treatment during the cocaine conditioning sessions, 
theoretically blunting the dopaminergic response to cocaine and the subsequent Pavlovian 
conditioning. In the initial self-administration experiment (Figure 5.11), mice had already 
learned the operant behavioral response to cocaine during the acquisition phase. When they then 
received KOR agonist injections, it is possible that they increased their self-administration 
behavior to overcome the blunting of the dopaminergic response to cocaine. We hypothesized 
that if mice were given KOR agonist injections during the initial acquisition phase, the effect 
would be similar to the CPP experiment in that the mice would not learn the operant behavioral 
response to cocaine.  
In contrast, we found that mice treated with nalfurafine immediately prior to these initial 
sessions also increased their cocaine self-administration compared to saline-treated animals 
(Figure 5.13). Previous studies of KOR agonists like U50,488 have shown a potentiation of 
cocaine reward, both using CPP18 as well as IVSA, at certain doses of cocaine. 118 Additionally, 
in a food vs cocaine-choice paradigm in rhesus monkeys, chronic U50,488 treatment increased 
responding for cocaine over food, even as it decreased responding rates overall.119,120 This is 
consistent with the idea that activation of the KOR decreases the reinforcing effects of drugs of 
abuse like cocaine, and that increased self-administration behavior is observed as animals require 
additional drug administration to reach the same levels of reward and dopamine release. 
The divergent effects of 3mg/kg U50,488 and 10ug/kg nalfurafine in cocaine CPP and 
cocaine IVSA highlight the differences between these assays. While both assays are commonly 
used to measure drug reward, studies have suggested that they do not measure the same reward 
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processes in the brain (reviewed in Bardo, 2000).121 Certain classes of drugs, such as the 
hallucinogen lysergic acid diethylamide (LSD), cause CPP in rats but are not self-administered, 
and others, such as pentobarbitol, are self-administered but do not cause CPP. Additionally, 
pretreatment of animals with D2-receptor antagonists blocks the self-administration of cocaine, 
but not cocaine CPP, again suggesting that these behaviors involve different mechanisms.  
A lower dose of 3µg/kg nalfurafine, however, blocked cocaine place preference (Figure 5.9 
B) and did not cause any measurable change in cocaine self-administration (Figure 5.12). Very 
low doses of nalfurafine have also been effective in blocking alcohol intake in animal models, 
especially in combination with naltrexone, a mu opioid antagonist and kappa opioid G-protein 
biased partial agonist.115 While additional experiments are necessary, these preliminary data, 
combined with the favorable post-marketing data from Japan, suggest that very low doses of 
nalfurafine could potentially be used to block drug reward. It is also possible that very low doses 
of U50,488 could have a similar effect, in light of the similar effects of 3mg/kg U50,488 and 
10µg/kg nalfurafine. Overall, these data suggest that relatively low doses of potent KOR 
agonists, or possibly partial agonists, may be able to successfully modulate cocaine-related 
behaviors at doses that do not cause the side effects that have hampered the development of KOR 
agonists previously.  
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CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
 There has been a great deal of work done over the past 50 years to investigate the effects 
of KOR agonists both in human and animal models of diseases, including addictive diseases. 
Here, we have added to this work with investigations of structurally-diverse KOR agonists and 
their effects on different KOR signaling modalities and behaviors.  
 In Chapter 3, 21 structurally diverse KOR agonists were tested for their G-protein versus 
b-arrestin-2 bias using cell-based functional assays. Several compounds tested had notable bias 
profiles, including the relatively unbiased salvinorin compounds. The morphinan compounds 
were especially G-protein biased, with the exception of nalfurafine, which was among the only 
b-arrestin-biased compounds reported here or elsewhere in the literature. We found that using 
heterologous cell lines for measuring G-protein activity may not accurately reflect signaling in 
the disease-relevant tissue, and future studies of G-protein signaling in brain homogenate tissue 
will be important for accurately profiling different KOR agonists. In particular, the ligand bias of 
nalfurafine varies widely in the literature, depending on assay and cellular context, and 
measurements of signaling in the relevant tissue will be important for understanding its in vivo 
effects in the future.  
 Despite these caveats, we identified a significant correlation between in vitro b-arrestin-2 
signaling, particularly the maximum efficacy in this signaling pathway, and the maximum 
sedative effect of KOR agonists in mice, measured by the rotarod assay. This supports previous 
studies that have suggested that arrestin recruitment is necessary for KOR-mediated sedation, 
and suggests that a G-protein biased KOR agonist may be beneficial for avoiding sedative side 
effects in therapeutic development. While studies in humans with non-selective G-protein biased 
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KOR agonists, like nalmefene and naltrexone, support this hypothesis, a KOR-selective G-
protein biased agonist has not been tested in humans.  
 In Chapter 4, we investigated the effects of these diverse KOR agonists on two 
additional signaling pathways – ERK1/2 and mTOR. We did not find any evidence that either 
early G-protein or b-arrestin-2 signaling pathway directly or uniquely activated ERK1/2 or 
mTOR, suggesting that these pathways should be studied independently in the future. Future 
studies are also needed to further investigate the relationship between KOR-mediated behavior 
and ERK1/2 and mTOR signaling pathways. Additionally, we compared protein-receptor 
interactions at the KOR after activation by several different KOR ligands and found that ligand 
bias could affect these interactions. Future studies will focus on identifying the effect of different 
KOR agonists on other signaling pathways, such as  14-3-3 signaling, as well as the role of these 
pathways and proteins in KOR-mediated effects in vivo.  
 In Chapter 5, we examined the effects of pharmacologically distinct KOR agonists on 
behaviors in mice. In particular, we found that the extremely G-protein biased agonist BPHA 
was still able to cause aversion, but not sedation, at high doses. We also investigated the effects 
of nalfurafine – the only KOR-selective agonist to be used clinically in humans, albeit only in 
Japan currently. We found that nalfurafine could block cocaine-reward without causing aversion 
at very low doses (3µg/kg), and that slightly higher doses (10µg/kg) caused an increase in 
cocaine intake – likely as compensation for decreasing the reinforcing effects of cocaine. Similar 
results with a low dose of 3mg/kg U50,488 suggests that decreasing the reinforcing effects of 
cocaine may be a feature of KOR activation, and not unique to nalfurafine. These data suggest 
that a very low dose of a potent KOR agonist, or perhaps a partial agonist, could be effective for 
modulating cocaine reward without causing aversive or sedative side effects. Additional 
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experiments in preclinical models, and likely humans, are needed to determine how to translate 
this effect into a desirable therapeutic response. 
 KOR agonists have been shown previously to both block and potentiate the rewarding 
and reinforcing effects of drugs of abuse like cocaine. It is apparent that the KOR system is 
involved in drug-related behaviors and reward, however the side effects such as sedation, 
aversion and hallucinations have prevented KOR agonists from being tested in humans for this 
indication. While the psychotomimetic effects of KOR agonists can’t be tested in animal models, 
our data suggest that some of these side effects could be avoided by very low doses of KOR 
agonists, or agonists with specific pharmacological profiles, while still affecting the rewarding 
properties of cocaine. It is also likely that future studies investigating the effects of other 
signaling pathways, such as ERK1/2, mTOR or 14-3-3, could help to further narrow down a 
pharmacological profile for a KOR agonist with fewer side effects. These data also support the 
idea, first proposed by the Kreek lab, that a KOR-selective partial agonist could be used for the 
treatment of cocaine addiction. The development of novel KOR agonists, including partial 
agonists, agonists with unique signaling profiles and very potent agonists, will be essential for 
testing these hypotheses in the future. 
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